Best Clinical Practices for the Sleep Center Adjustment of Noninvasive Positive Pressure Ventilation (NPPV) in Stable Chronic Alveolar Hypoventilation Syndromes

NPPV Titration Task Force of the American Academy of Sleep Medicine

Task Force Members: Richard B. Berry, M.D. (Chair); Alejandro Chediak, M.D. (Vice-Chair); Lee K. Brown, M.D.; Jonathan Finder, M.D.; David Gozal, M.D.; Conrad Iber, M.D.; Clete A. Kushida, M.D., Ph.D.; Timothy Morgenthaler, M.D.; James A. Rowley, M.D.; Sally L. Davidson-Ward, M.D.

1Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL; 2Miami Sleep Disorders Center, South Miami, Florida; 3University of New Mexico Health Sciences Center, Albuquerque, NM; Department of Pediatrics; 4Division of Pulmonary Medicine, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine; 5Department of Pediatrics, University of Chicago, Chicago, IL; 6Department of Internal Medicine, University of Minnesota, Minneapolis, MN; 7Stanford University Center of Excellence for Sleep Disorders, Stanford, CA; 8Division of Pulmonary Medicine, Mayo Clinic Medical School, Rochester, MN; 9Division of Pulmonary, Critical Care & Sleep Medicine, Wayne State University School of Medicine, Detroit, MI; 10Division of Pediatric Pulmonology, Children’s Hospital of Los Angeles, Keck School of Medicine -University of Southern California, Los Angeles, California

Summary: Noninvasive positive pressure ventilation (NPPV) devices are used during sleep to treat patients with diurnal chronic alveolar hypoventilation (CAH). Bilevel positive airway pressure (BPAP) using a mask interface is the most commonly used method to provide ventilatory support in these patients. BPAP devices deliver separately adjustable inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). The IPAP and EPAP levels are adjusted to maintain upper airway patency, and the pressure support (PS = IPAP-EPAP) augments ventilation. NPPV devices can be used in the spontaneous mode (the patient cycles the device from EPAP to IPAP), the spontaneous timed (ST) mode (a backup rate is available to deliver IPAP for the set inspiratory time if the patient does not trigger an IPAP/EPAP cycle within a set time window), and the timed (T) mode (inspiratory time and respiratory rate are fixed). During NPPV titration with polysomnography (PSG), the pressure settings, backup rate, and inspiratory time (if applicable) are adjusted to maintain upper airway patency and support ventilation. However, there are no widely available guidelines for the titration of NPPV in the sleep center. A NPPV Titration Task Force of the American Academy of Sleep Medicine reviewed the available literature and developed recommendations based on consensus and published evidence when available. The major recommendations derived by this consensus process are as follows:

General Recommendations:
1. The indications, goals of treatment, and side effects of NPPV treatment should be discussed in detail with the patient prior to the NPPV titration study.
2. Careful mask fitting and a period of acclimatization to low pressure prior to the titration should be included as part of the NPPV protocol.
3. NPPV titration with PSG is the recommended method to determine an effective level of nocturnal ventilatory support in patients with CAH. In circumstances in which NPPV treatment is initiated and adjusted empirically in the outpatient setting based on clinical judgment, a PSG should be utilized if possible to confirm that the final NPPV settings are effective or to make adjustments as necessary.
4. NPPV treatment goals should be individualized but typically include prevention of worsening of hypoventilation during sleep, improvement in sleep quality, relief of nocturnal dyspnea, and providing respiratory muscle rest.
5. When OSA coexists with CAH, pressure settings for treatment of OSA may be determined during attended NPPV titration PSG following AASM Clinical Guidelines for the Manual Titration of Positive Airway Pressure in Patients with Obstructive Sleep Apnea.
6. Attended NPPV titration with PSG is the recommended method to identify optimal treatment pressure settings for patients with the obesity hypoventilation syndrome (OHS), CAH due to restrictive chest wall disease (RTCD), and acquired or central CAH syndromes in whom NPPV treatment is indicated.
7. Attended NPPV titration with PSG allows definitive identification of an adequate level of ventilatory support for patients with neuromuscular disease (NMD) in whom NPPV treatment is planned.

Recommendations for NPPV Titration Equipment:
1. The NPPV device used for titration should have the capability of operating in the spontaneous, spontaneous timed, and timed mode.
2. The airflow, tidal volume, leak, and delivered pressure signals from the NPPV device should be monitored and recorded if possible. The airflow signal should be used to detect apnea and hypopnea, while the tidal volume signal and respiratory rate are used to assess ventilation.
3. Transcutaneous or end-tidal PCO₂ may be used to adjust NPPV settings if adequately calibrated and ideally validated with arterial blood gas testing.
4. An adequate assortment of masks (nasal, oral, and oronasal) in both adult and pediatric sizes (if children are being titrated), a source of supplemental oxygen, and heated humidification should be available.

Recommendations for Limits of IPAP, EPAP, and PS Settings:
1. The recommended minimum starting IPAP and EPAP should be 8 cm H₂O and 4 cm H₂O, respectively.
2. The recommended maximum IPAP should be 30 cm H₂O for patients ≥ 12 years and 20 cm H₂O for patients < 12 years.
3. The recommended minimum and maximum levels of PS are 4 cm H₂O and 20 cm H₂O, respectively.
4. The minimum and maximum incremental changes in PS should be 1 and 2 cm H₂O, respectively.

Recommendations for Adjustment of IPAP, EPAP, and PS:
1. IPAP and/or EPAP should be increased as described in AASM Clinical Guidelines for the Manual Titration of Positive Airway Pressure in Patients with Obstructive Sleep Apnea until the following obstructive respiratory events are eliminated (no specific order): apneas, hypopneas, respiratory effort-related arousals, and snoring.
2. The pressure support (PS) should be increased every 5 minutes if the tidal volume is low (< 6 to 8 mL/kg).
3. The PS should be increased if the arterial PCO₂ remains 10 mm Hg or more above the PCO₂ goal at the current settings for 10 minutes or more. An acceptable goal for PCO₂ is a value less than or equal to the awake PCO₂.
4. The PS may be increased if respiratory muscle rest has not been achieved by NPPV treatment at the current settings for 10 minutes or more.
5. The PS may be increased if the SpO₂ remains below 90% for 5 minutes or more and tidal volume is low (< 6 to 8 mL/kg).

Recommendations for Use and Adjustment of the Backup Rate/Respiratory Rate:
1. A backup rate (i.e., ST mode) should be used in all patients with central hypventilation, those with a significant number of central apneas or an inappropriately low respiratory rate, and those who unreliably trigger IPAP/EPAP cycles due to muscle weakness.
2. The ST mode may be used if adequate ventilation or adequate respiratory muscle rest is not achieved with the maximum (or maximum tolerated) PS in the spontaneous mode.
3. The starting backup rate should be equal to or slightly less than the spontaneous breathing respiratory rate (minimum of 10 bpm).
4. The backup rate should be increased in 1 to 2 bpm increments every 10 minutes if the desired goal of the backup rate has not been attained.
5. The IPAP time (inspiratory time) should be set based on the respiratory rate to provide an inspiratory time (IPAP time) between 30% and 40% of the cycle time (60/respiratory rate in breaths per minute).
6. If the spontaneous timed mode is not successful at meeting titration goals then the timed mode can be tried.

Recommendations Concerning Supplemental Oxygen:
1. Supplemental oxygen may be added in patients with an awake SpO₂ < 88% or when the PS and respiratory rate have been optimized but the SpO₂ remains < 90% for 5 minutes or more.
2. The minimum starting supplemental oxygen rate should be 1 L/min and increased in increments of 1 L/min due every 5 minutes until an adequate SpO₂ is attained (> 90%).

Recommendations to Improve Patient Comfort and Patient-NPPV Device Synchrony:
1. If the patient awakens and complains that the IPAP and/or EPAP is too high, pressure should be lowered to a level comfortable enough to allow return to sleep.
2. NPPV device parameters (when available) such as pressure relief, rise time, maximum and minimum IPAP durations should be adjusted for patient comfort and to optimize synchrony between the patient and the NPPV device.
3. During the NPPV titration mask refit, adjustment, or change in mask type should be performed whenever any significant unintentional leak is observed or the patient complains of mask discomfort. If mouth leak is present and is causing significant symptoms (e.g., arousals) use of an oronasal mask or chin strap may be tried. Heated humidification should be added if the patient complains of dryness or significant nasal congestion.

Recommendations for Follow-Up:
1. Close follow-up after initiation of NPPV by appropriately trained health care providers is indicated to establish effective utilization patterns, remediate side effects, and assess measures of ventilation and oxygenation to determine if adjustment to NPPV is indicated.

Keywords: NPPV, NPPV titration, bilevel positive airway pressure, chronic hypoventilation, BPAP, sleep related breathing disorder; sleep disorders breathing

Citation: Berry RB; Chediak A; Brown LK; Finder J; Gozal D; Iber C; Kushida CA; Morgenthaler T; Rowley JA; Davidson-Ward SL. Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes. J Clin Sleep Med 2010;6(5):491-509.

1.0 INTRODUCTION

Compelling evidence exists to support the use of noninvasive positive pressure ventilation (NPPV) via mask during sleep in the management of selected chronic alveolar hypoventilation (CAH) syndromes in adults and children. Improved sleep, nocturnal arterial oxygen saturation, diurnal and nocturnal arterial PCO₂, and quality of life indicators have been ascribed to nocturnal respiratory assistance in a divergent spectrum of disorders. NPPV has been used in CAH syndromes secondary to central respiratory control disturbances (CRCD), restrictive thoracic cage disorders (RTCD), neuromuscular diseases (NMD), and the obesity hypoventilation syndrome (OHS). Application of NPPV via a mask interface avoids the morbidity involved with tracheostomy. The most common approach is delivery of bilevel positive airway pressure (BPAP) in which separately adjustable inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP) are delivered. The pressure support mode devices are inherently leak tolerant and therefore ideal for use with mask ventilation.

Clinical Guidelines for the manual titration of positive airway pressure titration in patients with obstructive sleep apnea have recently been published regarding adjustment of CPAP and BPAP. However, a standard approach to NPPV titration has not yet appeared in the published literature. Many sleep centers have limited experience in dealing with patients with CAH syndromes other than the obesity hypoventilation syndrome. Individual sleep centers that care for a large number of patients with CAH syndromes do have protocols. However, these are not widely available and may reflect a particular mix of patients (e.g., predominantly neuromuscular disease). Protocols for NPPV titration are available from individual NPPV device manufacturers but often contain device-specific recommendations. Recognizing the need for development of guidelines for NPPV titration using polysomnography (PSG), the AASM Board of Directors appointed the NPPV Titration Task Force to develop recommendations for NPPV titration during PSG in sleep centers. The goal of the NPPV Task Force was the development of evidence- and consensus-based standardized NPPV titration guidelines, with the underlying concept that a successful titration is one in which
there is an optimized trade-off between increasing pressure to yield efficacy in supporting ventilation and decreasing pressure to minimize emergence of pressure-related side effects.

2.0 METHODS

The AASM Board of Directors approved the development of NPPV titration recommendations in October of 2007 and approved the appointments of Task Force members in February 2008. The mandate for the scope of the titration recommendations included CAH syndromes due to defects in CRCD, RTCD, NMD, and OHS. The use of NPPV in patients with chronic obstructive pulmonary disease (COPD) was not included in the Task Force’s mandate, which also did not include establishing indications for NPPV treatment. A literature search was conducted using the key words: NPPV titration, mask ventilation, nasal ventilation, non-invasive positive pressure ventilation, kyphoscoliosis, NPPV treatment, bilevel positive airway pressure titration, bi-level pressure titration, BPAP titration, obesity hypoventilation syndrome, central hypoventilation, congenital central hypoventilation, neuromuscular disease (including ALS and muscular dystrophy), and BPAP adjustment. All literature searches were computer-based using PubMed. The objective was to identify all studies that described NPPV titration protocols and NPPV treatment of the disorders of interest. Additional publications were obtained by review of the bibliographies of the initial set of publications. The Task Force also reviewed NPPV titration protocols developed by industry for background information. However, these protocols were not used to support the final recommendations. All relevant publications were assigned an evidence level based on the classification shown in Table 1.

Summaries of studies relevant to the titration of NPPV are located in the Appendix. (The Appendix is available online only at www.aasmnet.org/jcsm.) The evidence grades listed indicate the level of evidence available to support the findings of the study. In most instances, studies were not designed to validate the NPPV titration protocol.

As high level evidence was lacking in most areas concerning NPPV titration, a consensus process was felt to be necessary in order to guide the process. The Rand/UCLA Appropriateness Method was selected for this purpose given its use by the AASM Standards of Practice Committee (SPC) and the Clinical Guidelines for the titration of CPAP and BPAP Task Force. The first conference call of the NPPV Task Force was held on October 8, 2008 to discuss the Rand consensus process and to assign literature search topics to the committee members. A set of potential recommendations was developed to reflect the available evidence and NPPV titration protocols supplied by device manufacturers and several sleep centers with experience in NPPV titration. The proposed ballot was discussed during a second conference call on December 8, 2008, and the task force members made recommendations for revisions. After compiling these revisions the first ballot was sent to task force members who then independently voted on the recommendations. For balloting, the possible recommendations were rated on a 9-point scale. The “classic” definition of agreement was assessed using definitions from the RAND manual: Agreement for or against: No more than 2 Task Force members rate the indication outside the 3-point region (1-3, 4-6, 7-9) containing the median. Disagreement: At least 3 Task Force members rate the indication in the 1-3 region, and at least 3 Task Force members rate it in the 7-9 region. Indeterminate: Criteria are not met for agreement or disagreement. A third conference call took place on Feb 27, 2009, to review the tabulated balloting and discuss areas in which no consensus was reached. A second ballot for items that did not reach consensus was created and distributed to task force members in March 2008. A third conference call on May 28, 2009, was convened to review the 2nd ballot results and reach consensus on the remaining items.

The recommendations in section 4.0 were developed based on the voting results. The nomenclature for the recommendations and levels of recommendation are listed in the Table 2. The recommendations were reviewed by the Task Force members.
Figure 1—Tracing of NPPV flow, pressure, leak, and tidal volume in a patient receiving BPAP in the ST mode

The backup rate is 12, and as the patient did not trigger a breath for 5 seconds, a machine triggered breath was provided (A). Note that spontaneous and machine triggered breaths have similar peak flows (B, C) but different durations and different tidal volumes. The negative pressure spike (A) is an artifact generated by the NPPV device to denote a machine triggered breath.

The definitions, protocols, procedures, and indications for the diagnosis and management of OSA as specified in the AASM Manual for the Scoring of Sleep and Associated Events (i.e., respiratory rules), and the clinical guidelines for titration of positive airway pressure for obstructive sleep apnea should be followed where applicable.58

3.0 BACKGROUND

Treatment with NPPV via mask has been used effectively in a broad spectrum of disorders with CAH. Many of the initial studies of NPPV used volume ventilators with a mask interface. The volume ventilators were set at relatively high tidal volumes (10-15 mL/kg) to compensate for leak. Today, the most common approach is to use a bilevel positive airway pressure (BPAP) device which delivers separately adjustable inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP).47 The IPAP and EPAP are adjusted to maintain upper airway patency and the IPAP-EPAP difference provides pressure support (PS) to augment tidal volume. The delivered tidal volume may vary depending on respiratory system impedance and the patient’s ventilatory effort. However, BPAP devices are relatively leak tolerant and are thus preferred for use with mask interfaces. Comparisons of volume and pressure preset NPPV have found similar effects on gas exchange and sleep quality.27,55 One study found more gastrointestinal side effects from volume preset NPPV.55 Volume preset NPPV devices may have advantages for individual patients. This document addresses only the use of BPAP devices for delivery of NPPV as these devices are available in sleep centers.

NPPV using BPAP may be delivered in the spontaneous mode (S) in which the patient determines the time spent in IPAP (within the device IPAPtime limits) as well as the respiratory rate. NPPV in the spontaneous-timed (ST) mode provides a backup rate to ensure a minimum respiratory rate (Figure 1). If the patient fails to initiate an IPAP/EPAP cycle within a time window based on the backup rate, the device will deliver a machine-triggered IPAP cycle for the inspiratory time (IPAP time) set by the prescribing physician. For example, if the back-up rate is 10 bpm, the time window following the previous breath is 6 seconds. If a spontaneous breath does not occur, the device provides a machine triggered breath. In the timed mode (T) the NPPV device delivers IPAP/EPAP cycles at a set respiratory rate with a set inspiratory time. Recently, volume targeted BPAP (VT-BPAP) has been developed in which the IPAP-EPAP difference is automatically adjusted to deliver a target tidal volume.5,11

NPPV is often initiated after an attended NPPV titration with PSG. This approach allows determination of an appropriate interface, NPPV mode, IPAP, EPAP, as well as backup rate and inspiratory time (IPAP time), if applicable. IPAP and EPAP can also be adjusted to eliminate obstructive apnea, hypopnea, respiratory effort related arousals (RERAs), and snoring. Some sleep centers use transcutaneous PCO2 monitoring, end-tidal PCO2, or arterial blood gas sampling to guide adjustments to the NPPV device. Monitoring respiratory muscle EMG is performed in some sleep centers to help assess if adequate respiratory muscle rest has been attained during the titration (Figure 2).

A NPPV delivery system consists of three main components: a NPPV device; a mask interface (nasal mask, nasal pillows mask, oronasal mask, or oral interface) held snug to the face by headgear; and a flexible hose that connects the device to the interface. NPPV devices used for titration with PSG also typically provide analog or digital outputs of flow, tidal volume, delivered pressure, and leak (total or unintentional depending on the manufacturer) that may be recorded along with other standard PSG information.

The optimal NPPV device settings may vary widely between patients with various disease processes. NPPV settings may result in variable minute ventilation in the same patient in response to changes in respiratory system impedance, progression of muscle weakness, or alterations in central control due to medications or the underlying disease process. Therefore,
adequate follow-up of the patient during NPPV therapy by a physician knowledgeable in the delivery of NPPV treatment is essential. The recommendations in this report pertain only to nighttime NPPV titration studies. However, some recommendations in this document may be applicable to alternative methods of NPPV titration when under the direction of a physician knowledgeable in NPPV treatment.

4.0 RECOMMENDATIONS

The following are recommendations of the NPPV Titration Task Force and the AASM Board of Directors. The scope of these NPPV titration recommendations is restricted to adult and pediatric patients with stable CAH due to NMD, RTCD, CRCD (congenital and acquired), and OHS. Patients with chronic obstructive pulmonary disease, Cheyne-Stokes respiration, and primary central sleep apnea (formerly known as idiopathic central sleep apnea) are excluded. The scope of these NPPV titration recommendations is restricted to pressure preset BPAP ventilation by mask as this is the type of ventilatory support available in most sleep centers. The scope of these NPPV titration recommendations does not address the indications for NPPV treatment. The goal of these NPPV titration guidelines is to outline a practical approach for the titration of NPPV in the sleep center that could be widely available to provide effective NPPV treatment. The titration guidelines do not assert that other careful approaches under knowledgeable physician direction would not constitute acceptable medical care.

The optimal setting for the nocturnal titration of NPPV is in an AASM-accredited sleep center or laboratory with personnel experienced with both NPPV titration and managing patients with hypoventilation such as a registered polysomnography technologist or sleep-trained respiratory therapist. The NPPV titration should be reviewed and treatment pressures selected by a physician board certified in sleep medicine.

It is understood that the recommendations for minimum and maximum IPAP and EPAP may be constrained by the specific BPAP device used during the titration protocol. Lastly, the expectation of the Task Force is that these recommendations should not be followed in a “cookbook” manner; instead, sleep technologists and clinicians should combine their experience and judgment with the application of these recommendations to attain the best possible titration for any given patient.

The AASM expects these recommendations to have a positive impact upon the practice of sleep medicine, patient treatment outcomes, and health care costs. These recommendations reflect the state of knowledge at publication and will be reviewed, updated, and revised as new information becomes available. It is important to note that most recommendations published in this report are not practice parameters, since the majority of these recommendations do not achieve the evidence level of typical practice parameters. Instead, most recommendations were developed using the consensus process, and the evidence grading was used only to indicate the level of evidence available to support the recommendations. AASM levels of recommendations (Table 2) are indicated in parentheses after each Task Force recommendation. Recommendations extracted from active AASM practice parameters are labeled “(Standard)” while those not based on published AASM practice parameters are labeled “(Consensus).”

4.1 General Recommendations for NPPV Titration

PSG Studies in the Sleep Center for Pediatric or Adult Patients with CAH.

Unless otherwise stated it is understood that the recommendations apply to both pediatric and adult patients undergoing NPPV titration with PSG. A flow diagram summarizing the recommendations for NPPV titration is shown in Figure 3.

4.1.1 The indications, goals of treatment, rationale for use, and side effects of NPPV treatment should be discussed in detail with the patient prior to the NPPV titration study. Careful mask fitting and a period of acclimatization to low pressure before the titration should be included as part of the NPPV protocol. (Standard A)

This recommendation is based on Standard level recommendation 4.3.4 (“The addition of a systematic educational program is indicated to improve PAP utilization”) in the 2006 practice parameters for the use of PAP devices53 and consensus agreement by the NPPV Titration Task Force. Orientation to the procedure...
Start BPAP in spontaneous mode with IPAP/EPAP 8/4 cm H₂O

Obstructive apnea

>>> YES

Titrate PAP per AASM Guidelines*

NO

Adequate Vₜ

>>> YES

Increase PS**

NO

Low Vₑ, low SpO₂, central apneas

YES

Adequate muscle rest

NO

Increase PS** or RR#

YES

Continue present settings

NO

Adequate SpO₂

NO

Add Oxygen##

YES

Switch to ST or T mode or ↑ rate if in ST or T mode

Adequate VE

Low RR and/or central apneas

YES

Adequate Vₑ

NO

Adequate VE

Low VE, low SpO₂, central apneas

NO

Adequate VE

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO

NO
can improve sleep quality and mask acceptance.⁵⁶ The patient should be carefully fitted with an appropriate mask with the goals of minimizing leak, maximizing comfort, and compensating for significant nasal obstruction. The patient should be acclimated to the NPPV equipment (i.e., wearing the interface with the pressure on) prior to “lights off.”⁴⁸ For pediatric patients, behavioral modification techniques may be implemented to increase the tolerability and potential adherence to PAP therapy,⁵⁷⁻⁵⁹ since children frequently have problems adjusting to PAP.

### 4.1.2 NPPV titration with polysomnography is the recommended method to determine an effective level of nocturnal ventilatory support in patients with known daytime or nocturnal hypoventilation.

In circumstances (based on clinical judgment) when NPPV treatment is initiated and adjusted empirically in the outpatient setting, a PSG should be utilized (if and when possible) to confirm that the final NPPV settings are effective or to make further adjustments as necessary. (Level A - Consensus)

This recommendation is based on consensus of the NPPV titration task force and is consistent with the recommendations for initiating PAP treatment in patients with OSA. Several studies documenting the effectiveness of NPPV in CAH syndromes used titration with PSG to determine the NPPV settings. These include studies in patients with NMD⁶⁰⁻⁶⁴ and OHS,¹³⁻¹⁴,²¹⁻²² In most of the studies, the titration protocols were not presented in detail. However, the stated goals of titration usually were to eliminate obstructive events and improve ventilation such that the SpO₂ was > 90% and the transcutaneous PCO₂ was less than a set goal (such as 45 to 50 mm Hg), if sufficient pressure to achieve these goals was tolerated.

NPPV treatment can be initiated without PSG.³⁴ In some situations, based on clinical judgment, treatment can be empirically initiated at low pressure settings. Treatment pressures are then increased as tolerated over days to weeks based on daytime PCO₂ measurements, nocturnal oximetry, subjective relief of symptoms, and in some cases nocturnal transcutaneous PCO₂ monitoring. Such an approach may be suitable when the patient has difficulty tolerating NPPV or the major treatment goal is palliation. Several of the studies documenting the efficacy of NPPV titration in CAH syndromes did not use PSG for NPPV titration. NPPV treatment was initiated in RTCD,²⁴⁻²⁸,³⁰ NMD,²⁶,³⁹ and OHS¹² patients without PSG for titration.

Many of these studies actually admitted patients to the hospital for NPPV treatment initiation (Appendix). In most settings today, hospital admission for NPPV titration alone would not be financially feasible or considered as medically necessary. A randomized trial of inpatient versus outpatient initiation of home mechanical ventilation in patients with nocturnal hypoventilation found equivalent outcomes.⁶⁰ However, the patients did not have diurnal hypoventilation at baseline and PSG was not used to establish effectiveness of treatment. Outpatient initiation of NPPV without a PSG titration requires an experienced team of providers (physicians and respiratory therapists) as well as systematic approach to intervene for initial problems and for careful follow-up.

Attended NPPV titration with PSG has a number of advantages.⁶¹ These include documentation of the effects of NPPV on sleep quality, obstructive apnea and hypopnea, ventilation, and nocturnal gas exchange. The NPPV device settings (EPAP, IPAP, backup rate, inspiratory time) can be manually adjusted to deliver adequate nocturnal ventilation and improve or normalize nocturnal PCO₂. If necessary, supplemental oxygen can also be added. Mask interfaces can be changed or adjusted to maximize comfort and minimize leak. The PSG can document the effectiveness of NPPV settings in various body positions and sleep stages. It is common for NMD, RTCD, and OHS patients to have the most severe degree of hypoventilation during REM sleep.⁶² Therefore, it is important to document that NPPV settings selected for chronic treatment are effective in that situation.

Studies in patients with OHS¹¹ and NMD¹³ have documented disturbances in sleep quality due to patient-NPPV device asynchrony. Other studies noted that leak (particularly mouth leak)⁶⁴⁻⁶⁶ also resulted in sleep disturbance and reduced the effectiveness of NPPV. Such sleep disturbance and problems with leak would usually not be recognized without PSG. Fanfulla and coworkers⁶⁹ found that empiric NPPV settings that were effective and well tolerated during the day were associated with a substantial frequency of ineffective respiratory efforts and worsened sleep quality at night. Guo et al.²¹ found that PSG detected periods of patient-NPPV device desynchronization (uncoupling of the onset of the patient’s respiratory effort as detected by thoraco-abdominal movement and the onset of an IPAP/EPAP pressure cycle), periodic breathing, or auto-triggering in a group of OHS patients chronically treated with NPPV. Desynchronization was present in 55% of the patients studied and was associated with arousals. These episodes were often not associated with changes in either transcutaneous PCO₂ or oximetry. NPPV titration with PSG or PSG during treatment on the empirically selected NPPV settings would therefore be necessary to identify desynchronization or arousals from leaks.

### 4.1.3 The goals of NPPV titration and treatment should be individualized. Different levels of NPPV support may be needed depending on the specific goals in an individual patient.

Attended NPPV titration with polysomnography is the standard method to determine an effective level of NPPV support when the treatment goal is (are) to (1) reduce sleep fragmentation and improve sleep quality, (2) decrease the work of breathing and provide respiratory muscle rest, (3) normalize or improve gas exchange, and (4) relieve or improve nocturnal symptoms in patients with nocturnal hypoventilation. (Level A - Consensus)

This recommendation is based on consensus of the NPPV titration task force and acknowledges that titration goals may vary based on the individual case characteristics and by CAH etiology. Two published studies documented an improvement in sleep quality with NPPV treatment.⁶²,⁶³ If palliation is the main goal, finding a tolerable level of NPPV that improved symptoms (nocturnal dyspnea, morning headache, frequent awakenings) would be the primary goal of NPPV titration and treatment.

Optimal titration of NPPV to decrease the work of breathing during sleep requires monitoring of tidal volume, respiratory rate, and possibly respiratory muscle EMG to document the impact of NPPV. Patients with respiratory muscle weakness often exhibit considerable EMG activity of the accessory muscles of respiration (sternocleidomastoid, scalene, and others) during sleep.⁶²,⁶⁶,⁷⁰ In addition, patients with respiratory muscle weak-
ness or increased work of breathing often have a pattern of rapid shallow breathing (low tidal volume, high respiratory rate). Evidence that NPPV has reduced work of breathing includes an increase in tidal volume, a reduction in respiratory rate, and absence or reduction of inspiratory EMG activity of the muscle of respiration compared to baseline levels or those on lower amounts of NPPV support (Figure 2). Evidence of reduced work of breathing as just described, or by other validated methods, in the course of NPPV titration serves as the metric of successful NPPV titration where respiratory muscle rest during sleep is desirable.

During attended NPPV titration gas exchange can be monitored by pulse oximetry and the arterial PCO$_2$ may be measured intermittently by arterial blood gas testing or continuously estimated by transtracheal PCO$_2$ or end-tidal PCO$_2$ monitoring to allow precise documentation of an adequate level of NPPV support.

4.1.4 In instances where OSA coexists with CAH, NPPV titration with polysomnography is the standard method to determine effective pressure settings for the treatment of OSA. (Level A - Standard) The titration of positive airway pressure to eliminate obstructive events should follow the AASM Clinical Guidelines for PAP Titration in Patients with Obstructive Sleep Apnea. (Level A - Consensus)

This recommendation is based on the Standard recommendation in the practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders and the consensus based AASM Clinical Guidelines for PAP titration in patients with Obstructive Sleep Apnea. The majority of patients with the obesity hypoventilation syndrome have discrete apneas and hypopneas. In addition, several studies of patients with chronic hypoventilation due to chest wall disorders and neuromuscular disorders also were found to have obstructive respiratory events during PSG. For example, in one study by Gonzalez and coworkers of patients with kyphoscoliosis the AHI averaged 13.9 events/hour. While concurrent OSA may be suspected in candidates for NPPV who report snoring and witnessed apnea, absence of these symptoms does not rule out significant obstructive events.

4.1.5 Attended NPPV titration with polysomnography is the standard method to identify optimal treatment pressure settings for patients with the OHS in whom NPPV treatment is indicated (Level A - Consensus).

This recommendation is based on the AASM Practice Parameters for PSG and the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. The majority of patients with OHS have obstructive sleep apnea. However, a minority simply have daytime hypoventilation that worsens during sleep in the absence of discrete obstructive events. This NPPV titration recommendation does not imply that CPAP may not be effective in preventing apnea, hypopnea, and snoring in individual OHS patients. Chronic CPAP treatment in OHS patients can also result in a reduction in daytime PCO$_2$ in some patients. However, many OHS patients require high levels of CPAP and may manifest residual arterial oxygen desaturation or continue to hypoventilate after upper airway patency is restored. In such patients BPAP (NPPV) has been proven effective and by augmenting ventilation may prevent the need for mechanical ventilation or supplemental oxygen. A recent randomized trial compared CPAP and BPAP for treatment of patients with OHS. Patients with significant residual desaturation (SpO$_2$ < 80% for > 10 min) on a level of CPAP that eliminated obstructive events, an acute rise in PCO$_2$ > 10 mm Hg during REM sleep, or an increase in PCO$_2$ > 10 mm Hg in the morning compared to the afternoon were excluded. An equivalent reduction in daytime PCO$_2$ was noted at 3 months in patient randomized to CPAP or BPAP. Adherence to the treatment modalities was also not significantly different. In the BPAP group the mean IPAP and EPAP levels used were 16 and 10 cm H$_2$O, respectively, and the spontaneous mode of BPAP was employed. A few patients in both groups required supplemental oxygen in addition to PAP. Of note, the most severe OHS patients were excluded from this study and were treated with NPPV outside of the study protocol. OHS patients may require high levels of EPAP to prevent obstructive apnea and this tends to limit the available range of pressure support unless very high IPAP levels are used. In a study of the effect of NPPV in OHS patients by Berger and coworkers, EPAP values up to 14 cm H$_2$O and IPAP values up to 25 cm H$_2$O were needed. The mean IPAP and EPAP values were 18 and 8 cm H$_2$O, respectively.

4.1.6 Attended NPPV titration with polysomnography is the recommended method to identify an effective level of ventilatory support for patients with RTCD in whom NPPV treatment is indicated. (Level A - Consensus)

This recommendation is based on consensus of the NPPV titration task force. Several studies have documented an improvement in quality of life and gas exchange in patients with RTCD. To date, most published studies concerning NPPV treatment in RTCD patients have not used an attended NPPV titration study to select levels of pressure. However, in one study patients were admitted to the hospital for initiation of NPPV. Treatment NPPV settings were based on daytime arterial blood gas testing, nocturnal oximetry, or nocturnal transtracheal PCO$_2$ monitoring. One study also used nocturnal monitoring of arterial blood gases. In this study, the mean IPAP and EPAP values were 21.1 and 3.1 cm H$_2$O, respectively, with a backup rate of 20 bpm. In this study improvement in daytime PCO$_2$ was correlated with the amount of pressure support. A study by Gonzalez and coworkers used a mean backup rate of 15 bpm.

4.1.7 Attended NPPV titration with polysomnography should be performed before NPPV treatment in patients with acquired or congenital CRCD when NPPV treatment is deemed indicated. (Level A - Consensus)

This recommendation is based on consensus of the NPPV titration task force. Some patients with CRCD such as those with congenital central hypoventilation may have life-threatening events if not adequately ventilated during sleep. In these patients, documentation of the adequacy of NPPV treatment settings is essential before chronic NPPV treatment can be safely initiated. Patients with congenital central hypoventilation often require tracheostomy and volume ventilation from birth at least during sleep. Those patients who do not require daytime ventilation or supplemental oxygen.
ventilation may be transitioned to NPPV if they are motivated, found to be reliably adherent, and a sleep study documents efficacy of NPPV. Often the transition to NPPV occurs when the patient attains an age sufficient to accept mask ventilation. However, selected patients have used NPPV from a very early age. A potential complication of early use of mask ventilation is development of central facial hypoplasia, possibly due to chronic mask pressure. This is most likely to occur in patients needing mask ventilation during the day as well as during sleep.

4.1.8 Attended NPPV titration with polysomnography allows definitive identification of an adequate level of ventilatory support for patients with NMD in whom NPPV treatment is planned. (Level A - Consensus)

This statement is based on consensus of the NPPV task force. Numerous studies have demonstrated benefits in patients with NMD although the benefits may vary depending on the specific disorder. Attended NPPV titration with PSG in NMD patients can provide rapid determination of an adequate level of support, intervention for obstructive sleep apnea if present, and documentation of the effectiveness of the chosen NPPV settings in various sleep stages and body positions. Interventions for mask and leak problems can be made quickly. A number of studies in NMD patients did employ NPPV titration with PSG.

It is acknowledged that some centers with considerable expertise in treating patients with NMD (e.g., ALS) have a structured program for initiating NPPV on an outpatient basis during the daytime. NMD patients are often started on BPAP at low pressures (IPAP = 8, EPAP = 4) after a period of daytime adaptation under direct supervision. If patients tolerate nocturnal NPPV with low pressures, the settings are increased over weeks to months based on symptoms and/or daytime arterial PCO₂ measurement (or estimates of arterial PCO₂ such as end-tidal PCO₂). In one study of this approach in ALS patients, symptom relief was provided in 4 of 18 patients with the low initial settings, while most other patients required either one or two increases in pressure. Only 6/19 required a pressure support over 10 cmH₂O. In patients with rapidly progressive NMD, the main goal of treatment is often palliation of symptoms and improvement in quality of life rather than normalization of nocturnal arterial PCO₂.

In a randomized controlled study of the effect of BPAP in the ST mode on survival and quality of life in ALS, the average IPAP and EPAP settings were 15 and 6 cmH₂O, respectively. In this study only the subgroup of ALS patients without moderate to severe bulbar dysfunction had improved survival. However, all patients treated with NPPV had improvement in the quality of life. Patients with bulbar involvement may have more difficulty tolerating NPPV and mask ventilation. These patients may also have a greater risk of aspiration than those without upper airway dysfunction.

4.2 Recommendations Concerning the NPPV Device, Monitoring, Interfaces, and Other Equipment for NPPV Titration

4.2.1 Recommendations for the NPPV device used for titration

4.2.1.1 The NPPV device used for NPPV titration should have the ability to function in the spontaneous [support] (S), spontaneous/timed [support/timed] (ST), and timed (T) modes. Ideally the device should provide analog or digital outputs of flow, pressure, leak, and tidal volume that may be recorded during polysomnography. (Level A - Consensus)

This recommendation is based on consensus of the NPPV titration task force. Patients with OHS may not require a backup rate. However, patients with severely defective central control of ventilatory drive often require a backup rate to prevent central apneas and/or hypoventilation. In patients with respiratory muscle weakness or decreased respiratory system compliance, feeble inspiratory efforts may fail to reliably trigger an IPAP/EPAP cycle; such patients often benefit from a backup rate. The timed mode is infrequently used in sleep centers. However, there are individual patients who are more adequately treated with the timed mode than the ST mode. The timed mode employing a set respiratory rate that is typical higher than the native rate may result in a more stable pattern of ventilation in some patients. Parreira and coworkers compared the spontaneous and timed modes in normal subjects awake and asleep. Using the timed mode, they were able to deliver higher minute ventilation at lower IPAP than with the spontaneous mode and the patient’s sleeping breathing rate. Of note, a relatively high respiratory rate of 20 was used in the timed mode, with an inspiratory/expiratory ratio of 1 to 2. These findings may not generalize to patients with hypoventilation but illustrate the point that the timed mode or the ST mode with a relatively high rate is an option that could be tried in patients who do not tolerate high IPAP or in whom the maximally tolerated pressure support at the spontaneous respiratory rate does not deliver adequate minute ventilation. This may be a particularly effective strategy in patients with RTCD and reduced respiratory system compliance, in whom a high PS may be required to augment tidal volume.

4.2.2 Recommendations for parameters that should be recorded during the NPPV titration

4.2.2.1 Recording the airflow signal directly obtained from the NPPV device (derived from the accurate internal flow sensor) is the recommended method for monitoring airflow and detecting apneas and hypopneas during NPPV titration. (Level A - Consensus)

4.2.2.2 Measurement of airflow using a thermal device or a nasal pressure cannula under the mask is not recommended. Thermal device signals are not proportional to flow, and a nasal pressure cannula may cause problems with the mask seal and result in undesired leak. (Level A - Consensus)

4.2.2.3 Sawtooth patterns in the unfiltered inspiratory airflow or mask pressure tracings and/or detection of vibration by piezoelectric transducers or microphones applied to the neck are acceptable methods for detecting snoring during NPPV titration (Level A - Consensus).

Recommendations 4.2.2.1 to 4.2.2.3 are based on consensus of the NPPV titration task force and are consistent with the recommendations contained in the AASM clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea.
NPPV devices designed for titration during polysomnography generate a digital or analog flow signal based on accurate flow sensors within the device. The majority also provide signals reflecting an estimate of leak and tidal volume as well as the delivered pressure. During NPPV titrations, the use of a standard nasal pressure sensor placed under the nares is problematic due to the difficulty in obtaining a good PAP mask seal, since the tubing must pass underneath the mask to reach the nares. The use of thermal devices under the mask is also not recommended, as the signal is not proportional to airflow. The flow output from most NPPV devices while accurate for assessing airflow and flow limitation is often too filtered or under-sampled to display snoring.

4.2.2.4 The NPPV device estimate of tidal volume derived from an accurate internal flow sensor is an acceptable method to estimate tidal volume. The tidal volume signal obtained from the NPPV device should be recorded if possible. (Level A - Consensus)

This recommendation is based on consensus of the NPPV titration task force. While the flow signal readily allows detection of apnea and hypopnea, it may be more difficult to visually estimate a tidal volume that depends on both the inspiratory time was well as flow amplitude. Devices used for NPPV titration in sleep centers generally provide an analog or digital output of the estimated tidal volume derived from integration of the flow signal produced by an accurate flow sensor in the device. A breath-by-breath estimate of tidal volume is almost always available for display in the software or on the peripheral device measuring the NPPV device. However, recording the tidal volume signal (Figure 1) clearly show trends and variation during acquisition and may benefit the physician reviewing the study. The product of the estimated tidal volume and respiratory rate provides an estimate of the minute ventilation.

4.2.2.5 The NPPV device measurement of delivered pressure using an accurate internal pressure sensor is an acceptable method to estimate delivered pressure. Measurement of pressure at the mask or device outlet using an accurate pressure transducer is also an acceptable method of determining delivered pressure. A signal reflecting delivered pressure (at the machine or mask) should be recorded if possible. (Level A - Consensus)

Recording of delivered pressure is helpful to the technologist and physician reviewing the sleep recording. The pressure signal clearly shows the IPAP/EPAP cycle and is especially helpful in determining the pattern of response of the NPPV device in situations where the backup rate frequently intervenes. Some NPPV devices output a brief signal (intentional artifact) before each machine triggered breath (Figure 1). Another method to identify machine triggered breaths is to observe that they often have a different inspiratory time than spontaneous breaths.

4.2.2.6 The NPPV device measurement of leak using an internal flow sensor is an acceptable method to estimate leak. A signal reflecting leak should be monitored and recorded if possible. (Level A - Consensus).

Recording of estimates of leak is helpful to the technologist and the physician reviewing the sleep recording. The total flow is partitioned into a bias portion (leak) and a variable portion (patient flow). The leak is composed of the intentional leak + unintentional leak (mask or mouth leak). The intentional leak is due to flow through the non-rebreathing orifice. This leak depends on the interface type and delivered pressure. In some NPPV devices, the leak signal reflects the total leak; in others, a mask interface can be specified and the leak signal reflects unintentional leak. Several studies have documented that leak, especially mouth leak, can impair the effectiveness of NPPV and sleep quality. As delivered pressure increases during the titration, the total leak will increase. Therefore, what constitutes an inappropriately high leak will depend on interface and pressure (see also 4.8.6).

4.2.2.7 Recording respiratory muscle EMG activity using bipolar surface electrodes may be useful during NPPV titration in patients with NMD and/or an increased effort of breathing. Adequate NPPV support for muscle rest is associated with the absence or decrease in inspiratory EMG activity of the respiratory muscles during NREM sleep. (Level A - Consensus)

Some sleep centers with considerable experience in NPPV titration in patients with muscle weakness routinely record surface EMG from respiratory muscles using bipolar electrodes with techniques similar to those used for recording the anterior tibialis EMG. Surface diaphragm EMG recording utilizes two electrodes about 2 cm apart horizontally in the seventh and eight intercostal spaces in the right anterior axillary line. The right side of the body is used to reduce EKG artifact. Other sites include the sternocleidomastoid (an accessory muscle of respiration) and the right parasternal intercostal muscle (2nd and 3rd intercostal spaces in the mid-clavicular line). In normal individuals, the accessory muscles are usually quiet during sleep except during periods following arousal. Inspiratory EMG activity is noted in the intercostal muscles and the diaphragm during NREM sleep. During REM sleep, the intercostal activity is inhibited but diaphragmatic activity persists (although frequently diminished during bursts of eye movements). In contrast, in patients with respiratory muscle weakness or increased work of breathing, the EMG of accessory muscles often shows inspiratory activity during NREM sleep. During the NPPV titration, a reduction in the EMG activity of respiratory muscles (accessory, intercostals, diaphragm) may be a useful indicator that sufficient pressure support is being administered to allow muscle rest (Figure 2).

4.2.2.8. Recommendations for the measurement of PCO2 during NPPV titration

4.2.2.8.1 Arterial blood gas testing at a given level of NPPV support (once settings have been optimized or in the morning after a night of NPPV) is the most accurate method for determining the effects of NPPV on the arterial PCO2. Capillary blood gas testing is an acceptable alternative to arterial blood gas testing. (Level A - Consensus)

Determination of the arterial PCO2 by arterial blood gas sampling is the gold standard but is invasive, and arterial blood gas sampling requires special expertise. In addition, rapid access to a laboratory where the sample can be processed may be prob-
lematic for sleep centers located outside of hospital. In pediatric patients, sampling of a capillary blood gas (arterialized blood) is often used as an alternative to arterial blood gas testing. Another limitation of arterial blood gas monitoring is that serial testing during sleep requires either an indwelling catheter or repeated arterial punctures, and obtaining a sample may well cause arousal and a change in the PCO$_2$.

4.2.2.8.2 TRANSCUTANEOUS CO$_2$ (PtcCO$_2$) MONITORING MAYBE USEFUL FOR NPPV TITRATION WHEN THE DEVICE IS CALIBRATED AND THE READINGS ARE WITHIN 10 MM Hg OF THE CONCURRENT PCO$_2$ VALUE OBTAINED BY ARTERIAL BLOOD GAS (OR CAPILLARY BLOOD GAS) TESTING DURING STABLE BREATHING. DUE TO A SLOW RESPONSE TIME, CHANGES IN PtcCO$_2$ GENERALLY ARE DELAYED FOLLOWING CHANGES IN THE ARTERIAL PCO$_2$. (LEVEL A - CONSENSUS)

There have been relatively few studies of the performance of transcutaneous CO$_2$ (PtcCO$_2$) monitoring during NPPV titration and treatment. Storre and coworkers compared 250 paired samples of arterial blood gas and PtcCO$_2$ measurements in a group of 8 subjects undergoing NPPV for acute or chronic hypoventilation due to chronic obstructive pulmonary disease. They found that the PtcCO$_2$ provided a reasonable estimate of arterial blood gases, with the best results obtained by comparing a given arterial PCO$_2$ value with a PtcCO$_2$ result two minutes later. In an earlier study, Sanders et al. did not find transcutaneous PCO$_2$ to be a valid indicator of the arterial PCO$_2$ during sleep. Pavia and coworkers performed transcutaneous PCO$_2$ monitoring during NPPV and documented nocturnal hypoventilation (PtcCO$_2$ > 50 mm Hg) in 21 patients of a group of 50 with normal daytime PCO$_2$ (capillary blood gas) who had no nocturnal desaturation on oximetry. Certainly the information supplied by transcutaneous PCO$_2$ may be very useful if the accuracy can be verified. The ideal situation is one in which the PtcCO$_2$ device is calibrated before monitoring and the results are validated by ABG sampling at least at the start of or during the study. Caution is advised in making clinical decisions based on transcutaneous PCO$_2$ monitoring alone especially if the results do not correlate with other findings.

4.2.2.8.3 END-TIDAL PCO$_2$ (P$_e$CO$_2$) MONITORING MAY BE USEFUL DURING NPPV TITRATION. IDEALLY, THE ACCURACY OF P$_e$CO$_2$ SHOULD BE VALIDATED BY CONCURRENT PCO$_2$ MEASUREMENT USING ARTERIAL OR CAPILLARY BLOOD GAS TESTING DURING STABLE BREATHING. P$_e$CO$_2$ VALUES THAT DIFFER BY LESS THAN 10 MM Hg FROM THE ARTERIAL (OR CAPILLARY) VALUE INDICATE A VALID READING. SAMPLING OF GAS AT THE NARES RATHER THAN AT THE MASK IS REQUIRED FOR OPTIMAL MEASUREMENT OF P$_e$CO$_2$ DURING NPPV TITRATION. IF THE PLATEAU IS LOST FROM THE P$_e$CO$_2$ WAVEFORM DURING THE TITRATION, THE MEASUREMENT CAN NO LONGER BE CONSIDERED ACCURATE. IF SIGNIFICANT LUNG DISEASE IS PRESENT, THE DIFFERENCE BETWEEN THE P$_e$CO$_2$ AND THE ARTERIAL PCO$_2$ OFTEN EXCEEDS 10 MM Hg. FOR THIS REASON, END-TIDAL PCO$_2$ MEASUREMENT IS LESS FREQUENTLY USED IN PATIENTS WITH CAH WHO HAVE SIGNIFICANT CONCURRENT LUNG DISEASE. (LEVEL A - CONSENSUS)

This recommendation is based on consensus of the NPPV titration task force. We know of no published study that documents the accuracy of monitoring end-tidal PCO$_2$ during NPPV titration. Of note, Sanders and coworkers found poor agreement between end-tidal PCO$_2$ and arterial blood gas testing in adult patients during diagnostic polysomnography. However, gas was sampled from a mask covering the nose and mouth rather than the nares. In contrast Kirk and coworkers found reasonable agreement between end-tidal PCO$_2$ and transcutaneous PCO$_2$ during pediatric polysomnography. In the commonly used side-stream capnography method, exhaled gas is suctioned via a nasal cannula to an external CO$_2$ sensor. The major challenge for end-tidal PCO$_2$ monitoring during NPPV titration is dilution of the exhaled sample by flow from the NPPV device (especially if gas is sampled at the mask). One approach is to have the patient wear a sampling nasal cannula under the NPPV mask interface. Using this approach gas is sampled as it is exhaled from the nares rather than suctioned from the mask. A similar method was used by Parreira and coworkers during their study of bilevel PAP in normal subjects. A disadvantage of this approach is that the presence of the cannula passing under the nasal or oronasal mask seal could cause excessive leak. If an oral mask is used the sampling catheter would be directly connected to the mask.

4.2.2.9 NPPV MASK INTERFACES AND HUMIDIFICATION FOR NPPV TITRATION

4.2.2.9.1 THERE SHOULD BE SEVERAL DIFFERENT TYPES OF PAP INTERFACES (I.E., NASAL MASKS, NASAL PILLOWS, ORONASAL MASK) AND ACCESSORIES (CHINSTRAPS, HEATED HUMIDIFIER) AVAILABLE IF THE PATIENT ENCOUNTERS PROBLEMS (E.G., MOUTH LEAK, NASAL CONGESTION) DURING THE NIGHT. THE PATIENT SHOULD BE ACCLIMATIZED TO THE INTERFACE AND THE MASK FIT TESTED WITH THE PRESSURE ON PRIOR TO “LIGHTS OFF.” (LEVEL A - CONSENSUS)

4.2.2.9.2 PEDIATRIC (IN ADDITION TO SMALL ADULT) INTERFACES SHOULD BE AVAILABLE FOR TITRATION IN PATIENTS LESS THAN 12 YEARS OLD. PEDIATRIC PATIENTS BENEFIT FROM INTRODUCTION TO POTENTIAL INTERFACES AND ACCUMULATION BEFORE THE NIGHT OF THE NPPV TITRATION. INTRODUCTION OF THE INTERFACES SHOULD BE DEVELOPMENTALLY APPROPRIATE FOR THE CHILD’S AGE AND MAY INCLUDE CHILD LIFE OR OTHER SUPPORT SERVICES PRIOR TO TITRATION. (LEVEL A - CONSENSUS)

Recommendations 4.2.2.9.1 and 4.2.2.9.2 are based on consensus of the NPPV titration task force and are consistent with the AASM clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea.

As mentioned in an earlier section, pediatric patients require an introduction to masks prior to the NPPV titration. A Child Life Specialist is an example of a trained professional with expertise in helping children and their families overcome challenging life events in the medical setting. A Child Life Specialist or similar professional with expertise in child development can help children and their families adapt to masks and NPPV titration.

4.2.2.9.3 HEATED HUMIDIFICATION SHOULD BE AVAILABLE FOR PATIENTS UNDERGOING NPPV TITRATION. THE ADDITION OF HUMIDIFICATION IS INDICATED IF THE PATIENT COMPLAINS OF SIGNIFICANT ORAL OR NASAL DRYNESS (UNLESS HUMIDIFICATION IS NOT TOLERATED BY THE PATIENT). (LEVEL A - CONSENSUS)

This recommendation is based on consensus of the task force. It is consistent with clinical guidelines for the manual titration of CPAP and BPAP in patients with OSA. The AASM Stan-
4.3 Recommendations for Initial and Maximum Pressures during NPPV Titration

4.3.1. The recommended minimum starting IPAP and EPAP should be 8 cm H\(_2\)O and 4 cm H\(_2\)O, respectively. (Level A - Consensus).

This recommendation is based on consensus agreement by the NPPV PAP Titration Task Force. An EPAP of 4 cm H\(_2\)O is the lowest available on most NPPV devices. The recommendation of a starting IPAP is based on the minimum recommended pressure support. These recommendations are consistent with the AASM Clinical Guidelines for the manual titration of PAP in patients with OSA.\(^{48}\)

4.3.2 The recommended minimum starting pressure support (difference between IPAP and EPAP) should be 4 cm H\(_2\)O. (Level A - Consensus)

This recommendation is based on consensus agreement by the NPPV Titration Task Force. While it is acknowledged that 4 cm H\(_2\)O provides only a modest degree of pressure support, starting at this level will allow adaptation to positive airway pressure.

4.3.3 The recommended maximum pressure support (difference between IPAP and EPAP) should be 20 cm H\(_2\)O. (Level A - Consensus)

This recommendation is based on consensus agreement by the NPPV titration task force. In the AASM clinical guidelines for titration of CPAP and BPAP, the recommended minimum IPAP-EPAP difference was 4 cm H\(_2\)O and the maximum was 10 cm H\(_2\)O. However, in the case of OSA, the major objective is to maintain airway patency. Budweiser and coworkers\(^{25}\) used a mean pressure support of 18 cm H\(_2\)O in a study of patients with RTCD. Patients with low respiratory system compliance may require high level of pressure support to augment ventilation during sleep.

4.3.4 The recommended maximum IPAP should be 20 cm H\(_2\)O for patients < 12 years and 30 cm H\(_2\)O for patients \(\geq 12\) years. (Level A - Consensus)

This recommendation is based on consensus agreement by the NPPV titration task force. The maximum IPAP available on most NPPV devices is 25 or 30 cm H\(_2\)O. A lower value for the maximum IPAP was recommended for patients less than 12 years of age in the clinical guidelines for manual titration of PAP in patients with OSA.\(^{48}\) It is acknowledged that individual patients may benefit from higher IPAP. High pressure levels are problematic for obtaining an adequate mask seal and often require significant mask tightening. There have been reports of changes in facial structure associated with NPPV in children.\(^{74,75}\) Although it is not known whether the interface itself or the pressure delivered is the issue, it seems prudent to avoid very high pressures if possible in children.

4.3.5 The minimum and maximum incremental changes in PS during NPPV titration should be 1 and 2 cm H\(_2\)O, respectively. (Level A - Consensus).

This recommendation is based on consensus agreement by the NPPV titration task force. Although smaller pressure changes than 1 cm H\(_2\)O are possible, such changes are unlikely to be clinically meaningful. A maximum incremental change of 2 cm H\(_2\)O is recommended to avoid over titration.

4.4 Recommendations for the Adjustment of Pressure Support During NPPV Titration (see Figure 3)

4.4.1 IPAP and EPAP should be adjusted to eliminate obstructive apneas, hypopneas, RERAs (respiratory effort related arousals), and snoring following the AASM Clinical Guidelines for the Manual Titration of PAP in Patients with OSA. (Level A - Consensus)

Recommendation 4.4.1 is based on a consensus of the NPPV titration task force and is consistent with the AASM clinical guidelines for PAP titration in patients with OSA.\(^{48}\) These guidelines provide a protocol for increasing in the IPAP and EPAP to eliminate obstructive apneas, hypopneas, RERAs, and snoring.

4.4.2 Recommendations for adjusting pressure support for low tidal volume or hypoventilation during sleep

4.4.2.1 The PS should be increased every 5 minutes if the tidal volume is below the acceptable goal. An acceptable tidal volume goal for most patients ranges from 6 to 8 mL/kg using ideal body weight (Figure 3). (Level A - Consensus).

Recommendation 4.4.2.1 is based on consensus of the NPPV titration task force. An acceptable tidal volume may vary with the disorder being treated and the respiratory rate. Tidal volumes of 6 to 8 mL/kg at typical respiratory rates usually de-
liver normal minute ventilation. In patients with hypercapnia, a small increase or decrease in alveolar ventilation results in a relatively large decrease or increase in the PCO$_2$ due to the hyperbolic relationship between the two variables. If lung disease is present, a higher minute ventilation is needed to deliver adequate alveolar ventilation due to an increase in physiological dead space. In normal individuals, the dead space is approximately equal to 2 mL/kg. The recommended tidal volume target for volume targeted BPAP is 8 mL/kg using ideal body weight. Slightly lower tidal volumes with higher respiratory rates may be better tolerated in individual patients (particularly in RTCD). It should also be noted that a reduction in leak by mask refit or change may improve the effectiveness of the current PS. Therefore, intervention for leak should be considered especially if prior increases in PS have been ineffective with respect to increasing tidal volume. The accuracy of NPPV device estimates of tidal volume is dependent on the accuracy of the flow signal. If the accuracy of the flow signal is degraded by mouth leak (nasal mask) or high mask leak, then the estimated tidal volume may not accurately reflect the tidal volume of the patient. Discrepancy between device estimates of tidal volume and the clinical scenario (including other related sensors) should prompt the technologist to check for excessive leak. As an example, increases in the pressure support (difference between IPAP and EPAP) that fail to raise tidal volume might herald excessive leak.

4.4.2.2 The PS should be increased if the arterial PCO$_2$ remains 10 mm Hg above goal at the current settings for 10 minutes or more. An acceptable goal for PCO$_2$ is a value less than or equal to the awake PCO$_2$ (Figure 3). (Level A – Consensus).

4.4.2.3 The PS should be increased in 1 to 2 cm H$_2$O increments if the transcutaneous PCO$_2$ or end-tidal PCO$_2$ remains 10 mm Hg or more above goal for 10 minutes or more. This assumes that these measurements of the PCO$_2$ have been documented to accurately reflect the arterial PCO$_2$ in a given patient (Figure 3). (Level A – Consensus).

Recommendations 4.4.2.2 and 4.4.2.3 are based on consensus of the NPPV titration task force.

It is acknowledged that not all sleep centers have the ability to measure transcutaneous or end-tidal CO$_2$ or the expertise to use the information. This recommendation is included for sleep centers who have the capability to make these measurements and routinely use them during NPPV titrations. Several of the studies included in the Appendix did utilize measurements of CO$_2$ to guide NPPV titration. It should be noted that in normal subjects there is a small increase in arterial PCO$_2$ during sleep of about 5 to 10 mm Hg. However, as most patients being treated with NPPV have daytime hypoventilation, one ideal goal of treatment would consist of preventing a further increase in the arterial PCO$_2$ during sleep. The daytime awake PCO$_2$ may decrease with chronic nocturnal NPPV treatment in a substantial number of patients with CAH. Thus, the level of nocturnal PCO$_2$ on NPPV may eventually be lower than the initial goal. On the other hand some patients may not initially tolerate a level of PS adequate to meet the chosen PCO$_2$ goal. However, both daytime and nocturnal PCO$_2$ may decrease over time with chronic NPPV treatment.

4.4.2.5 Pressure support may be increased if respiratory muscle rest has not been achieved by NPPV treatment at the current settings for 10 minutes of more. Adequate respiratory muscle rest during NPPV is associated with resolution or improvement in tachypnea and/or excessive inspiratory effort as measured by phasic EMG activity of inspiratory muscles (Figure 3). (Level A – Consensus)

This recommendation is based on consensus of the NPPV titration task force. As noted in a previous section, the accessory muscles of respiration are not normally active during sleep. The absence or decrease in accessory muscle EMG and a decrease in intercostal and diaphragmatic EMG would suggest that a given level of NPPV was providing respiratory muscle rest.

4.4.2.6 Pressure support may be increased if the SpO$_2$ remains below 90% for 5 minutes or more and tidal volume is low (< 6 to 8 mL/kg). If discrete obstructive apneas or hypopneas are present, the Clinical Guidelines for PAP titration in OSA Patients should be followed. (Level A - Consensus).

This recommendation is based on consensus of the NPPV titration task force. The rationale behind this recommendation is that an increase in pressure support may increase tidal volume and reduce or eliminate residual hypoventilation thereby improving oxygenation. If not successful the addition of supplemental oxygen may be needed. While criteria for chronic oxygen therapy often use a SpO$_2$ of less than 88% as an indication for supplemental oxygen, the slightly higher goal of 90% was chosen to allow for a margin error as the tidal volume associated with a level of pressure support could vary somewhat with the clinical condition of the patient. In addition, in some circumstances the pulse oximetry values can overestimate the actual arterial oxyhemoglobin saturation.

4.5 Recommendations for the Use of ST and Timed Modes

4.5.1 The ST Mode (backup rate) should be used in all patients with central hypoventilation or significantly impaired respiratory drive. If the ST Mode is not successful the Timed Mode with a fixed respiratory rate may be tried (Level A - Consensus).

4.5.2 The ST Mode (backup rate) should be used if frequent and significant central apneas are present at baseline or during the NPPV titration, if the respiratory rate is inappropriately low, or if the patient fails to reliably trigger the NPPV device to transition from EPAP to IPAP due to muscle weakness (Figure 3). If the ST Mode is not successful, the Timed Mode with a fixed respiratory rate may be tried (Level A - Consensus).

Recommendations 4.5.1 and 4.5.2 are based on consensus of the task force and the fact that patients with central hypoventilation by definition may fail to trigger an IPAP/EPAP cycle for an inappropriately long period (central apnea) or may have an inappropriately low respiratory rate to provide adequate minute ventilation. In addition, many patients with disorders such as central congenital hypoventilation will not respond to worsening hypoxemia with an increase in respiratory effort. Other patients with CAH may unreliably trigger IPAP/EPAP cycle due
to muscle weakness or develop central apnea during the NPPV titration. Given the fact that muscle strength may vary over time in patients with NMD, most clinicians would use a backup rate for chronic treatment in these patients even if not required during the NPPV titration. Several of the studies reviewed employed the ST mode in NMD,3,39,44 OHS,19 and RTCD.25,27,30

### 4.5.3 The ST Mode (backup rate) may be used if adequate ventilation or adequate respiratory muscle rest is not achieved with the maximum (or maximum tolerated) PS in the spontaneous mode. If the ST Mode is not successful, the Timed Mode with a fixed respiratory rate may be tried (Figure 3). (Level A - Consensus)

This recommendation is based on consensus of the task force. Using a higher respiratory rate can potentially deliver higher minute ventilation with the same tidal volume. However, at higher rates, the time for exhalation decreases. Choice of respiratory rate and inspiratory time are discussed below.

### 4.5.4 Recommendations for choosing the backup rate in the ST mode and the respiratory rate in the timed mode

#### 4.5.4.1 The starting backup rate for the ST mode should be equal to or slightly less than the patient’s spontaneous sleeping respiratory rate (minimum of 10 BPM). If the sleeping respiratory rate is not known, one may use the spontaneous awake respiratory rate. The initial setting for the respiratory rate in the timed mode should be equal or slightly less than the patient’s spontaneous sleeping respiratory rate or the current back-up rate if switching from the ST to Timed mode. (Level A – Consensus)

#### 4.5.4.2 The backup rate (ST Mode) or specified respiratory rate (Timed Mode) should be increased in increments of 1-2 breaths

#### 4.5.4.3 The backup rate (ST mode) or respiratory rate (Timed Mode) should be decreased if the patient reports discomfort thought to be related to a high respiratory rate or if NPPV device-triggered and patient-triggered breaths are frequently superimposed (stacking of breaths). (Level A – Consensus)

These recommendations (4.5.4.1 to 4.5.4.3) are based on consensus of the NPPV titration task force and review of industry protocols. In a study of NMD patients Katz and coworkers used a back-up rate 10% below that patient’s resting breathing rate. One industry protocol suggests starting at a minimum rate of 8 to 10 breaths per minute or 2 breaths per minute below the patient’s resting rate. Gonzales and coworkers used a backup rate of 15 in a group of patients with RTCD. Mellies et al.42 used backup rates ranging from 14 to 24 (mean 19.6) in a group of children with NMDs. Tuggey et al.27 used a mean backup rate of 15 in a study of NPPV and patients with RTCD, while another study25 used a backup rate of 20 breaths per minute in a similar population.

### 4.5.5 Recommendations for choice of the inspiratory time in the ST and timed modes

#### 4.5.5.1 The initial inspiratory time (IPAP time) for machine-triggered breaths in the ST mode or all breaths in the timed mode is chosen based on the respiratory rate and the need to provide both an adequate tidal volume and an appropriate inspiratory time to expiratory time ratio (I:E ratio). Another method of expressing the I:E ratio is the %IPAP time which is inspiratory time (IPAP time) as a % of the cycle time (Table 3). The recommended %IPAP time is usually between 30% and 40%. The default inspiratory time on NPPV devices is commonly 1.2 seconds. (Level A - Consensus)

#### 4.5.5.2 A shorter inspiratory time (%IPAP time of approximately 30%) may be useful in patients with concurrent obstructive airways disease (especially at higher respiratory rates) to allow adequate time for exhalation. A longer inspiratory time (%IPAP time of approximately 40%) may be useful in patients with restrictive disease such as RTCD (decreased respiratory system compliance). (Level A - Consensus)

#### 4.5.5.3 The inspiratory time in the ST or Timed modes should be adjusted to maximize ventilation, patient/NPPV synchrony, and patient comfort (Table 3). (Level A - Consensus)

The recommendations 4.5.5.1 to 4.5.5.3 are based on consensus agreement by the NPPV titration task force. When NPPV devices are used in the ST mode both the respiratory rate and the duration of IPAP (inspiratory time or IPAP time) for machine triggered breaths must be specified (although the devices do have default values). Specifying the respiratory rate specifies the cycle time (60 sec/respiratory rate in breaths per minute). As the respiratory rate increases the maximum IPAP time decreases for a given inspiratory/expiratory ratio (I/E ratio). A convenient method is to specify the %IPAP time (IPAP time X 100 / cycle time). In general the minimum recommended I:E

---

### Table 3

<table>
<thead>
<tr>
<th>%IPAPtime (%)</th>
<th>RR</th>
<th>Cycle Time (sec)</th>
<th>Inspiratory Time = IPAPtime (sec)</th>
<th>EPAPtime (sec)</th>
<th>I:E</th>
</tr>
</thead>
<tbody>
<tr>
<td>30%</td>
<td>10</td>
<td>6</td>
<td>1.8</td>
<td>4.2</td>
<td>1:2.3</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>5</td>
<td>1.5</td>
<td>3.5</td>
<td>1:2.3</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>4</td>
<td>1.2</td>
<td>2.8</td>
<td>1:2.3</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>3</td>
<td>0.9</td>
<td>2.1</td>
<td>1:2.3</td>
</tr>
<tr>
<td>40%</td>
<td>10</td>
<td>6</td>
<td>2.4</td>
<td>3.6</td>
<td>1:1.5</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>5</td>
<td>2.0</td>
<td>3.0</td>
<td>1:1.5</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>4</td>
<td>1.6</td>
<td>2.4</td>
<td>1:1.5</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>3</td>
<td>1.2</td>
<td>1.8</td>
<td>1:1.5</td>
</tr>
</tbody>
</table>

Inspiratory Time = IPAP time
%IPAP = IPAPtime X 100 / (IPAPtime+EPAPtime)
Cycle time = 60/respiratory rate in breaths per minute
Cycle time = (IPAPtime+EPAPtime)
I:E ratio = inspiratory time/expiratory time = IPAP time/EPAP time

---

4.5.4.1 The starting backup rate for the ST mode should be equal to or slightly less than the patient's spontaneous sleeping respiratory rate (minimum of 10 BPM). If the sleeping respiratory rate is not known, one may use the spontaneous awake respiratory rate. The initial setting for the respiratory rate in the timed mode should be equal or slightly less than the patient's spontaneous sleeping respiratory rate or the current back-up rate if switching from the ST to Timed mode. (Level A – Consensus)

4.5.4.2 The backup rate (ST Mode) or specified respiratory rate (Timed Mode) should be increased in increments of 1-2 breaths

4.5.4.3 The backup rate (ST mode) or respiratory rate (Timed Mode) should be decreased if the patient reports discomfort thought to be related to a high respiratory rate or if NPPV device-triggered and patient-triggered breaths are frequently superimposed (stacking of breaths). (Level A – Consensus)

These recommendations (4.5.4.1 to 4.5.4.3) are based on consensus of the NPPV titration task force and review of industry protocols. In a study of NMD patients Katz and coworkers used a back-up rate 10% below that patient's resting breathing rate. One industry protocol suggests starting at a minimum rate of 8 to 10 breaths per minute or 2 breaths per minute below the patient’s resting rate. Gonzales and coworkers used a backup rate of 15 in a group of patients with RTCD. Mellies et al. used backup rates ranging from 14 to 24 (mean 19.6) in a group of children with NMDs. Tuggey et al. used a mean backup rate of 15 in a study of NPPV and patients with RTCD, while another study used a backup rate of 20 breaths per minute in a similar population.

4.5.5 Recommendations for choice of the inspiratory time in the ST and timed modes

4.5.5.1 The initial inspiratory time (IPAP time) for machine-triggered breaths in the ST mode or all breaths in the timed mode is chosen based on the respiratory rate and the need to provide both an adequate tidal volume and an appropriate inspiratory time to expiratory time ratio (I:E ratio). Another method of expressing the I:E ratio is the %IPAP time which is inspiratory time (IPAP time) as a % of the cycle time (Table 3). The recommended %IPAP time is usually between 30% and 40%. The default inspiratory time on NPPV devices is commonly 1.2 seconds. (Level A - Consensus)

4.5.5.2 A shorter inspiratory time (%IPAP time of approximately 30%) may be useful in patients with concurrent obstructive airways disease (especially at higher respiratory rates) to allow adequate time for exhalation. A longer inspiratory time (%IPAP time of approximately 40%) may be useful in patients with restrictive disease such as RTCD (decreased respiratory system compliance). (Level A - Consensus)

4.5.5.3 The inspiratory time in the ST or Timed modes should be adjusted to maximize ventilation, patient/NPPV synchrony, and patient comfort (Table 3). (Level A - Consensus)

The recommendations 4.5.5.1 to 4.5.5.3 are based on consensus agreement by the NPPV titration task force. When NPPV devices are used in the ST mode both the respiratory rate and the duration of IPAP (inspiratory time or IPAP time) for machine triggered breaths must be specified (although the devices do have default values). Specifying the respiratory rate specifies the cycle time (60 sec/respiratory rate in breaths per minute). As the respiratory rate increases the maximum IPAP time decreases for a given inspiratory/expiratory ratio (I/E ratio). A convenient method is to specify the %IPAP time (IPAP time X 100 / cycle time). In general the minimum recommended I:E

---

#### Table 3

<table>
<thead>
<tr>
<th>%IPAPtime (%)</th>
<th>RR</th>
<th>Cycle Time (sec)</th>
<th>Inspiratory Time = IPAPtime (sec)</th>
<th>EPAPtime (sec)</th>
<th>I:E</th>
</tr>
</thead>
<tbody>
<tr>
<td>30%</td>
<td>10</td>
<td>6</td>
<td>1.8</td>
<td>4.2</td>
<td>1:2.3</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>5</td>
<td>1.5</td>
<td>3.5</td>
<td>1:2.3</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>4</td>
<td>1.2</td>
<td>2.8</td>
<td>1:2.3</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>3</td>
<td>0.9</td>
<td>2.1</td>
<td>1:2.3</td>
</tr>
<tr>
<td>40%</td>
<td>10</td>
<td>6</td>
<td>2.4</td>
<td>3.6</td>
<td>1:1.5</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>5</td>
<td>2.0</td>
<td>3.0</td>
<td>1:1.5</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>4</td>
<td>1.6</td>
<td>2.4</td>
<td>1:1.5</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>3</td>
<td>1.2</td>
<td>1.8</td>
<td>1:1.5</td>
</tr>
</tbody>
</table>

Inspiratory Time = IPAP time
%IPAP = IPAPtime X 100 / (IPAPtime+EPAPtime)
Cycle time = 60/respiratory rate in breaths per minute
Cycle time = (IPAPtime+EPAPtime)
I:E ratio = inspiratory time/expiratory time = IPAP time/EPAP time
turer's guidelines. The above recommendations are based on the manufac-
device. The above recommendations are confined to this
(Average Volume Assured Pressure Support or AVAPS, Philips-
date, only one VT-BPAP device is available in the United States
would deliver higher pressure support to return the delivered
liver a targeted tidal volume. For example, if respiratory muscle
advantage of automatically varying the pressure support to de-
the NPPV task force. Volume targeted BPAP has the potential
4.6.4 If Volume targeted pressure support is used in the ST
or timed modes, the backup rate and inspiratory time may be
chosen based on recommendations in the above sections.
(Level A - Consensus)

4.6.4. Optimally, supplemental O₂ should be connected to the
PAP device outlet (using a T-connector). (Level A - Consensus)

4.7.5 “Weaning” down of O₂ supplementation by employing a
higher PS or respiratory rate (if the patient tolerates these
increases) can be attempted. (Level A - Consensus)

Recommendations 4.7.1 to 4.7.5 are based on consensus and
are similar to recommendations for supplemental oxygen in the
AASM Clinical Guidelines for the Manual Titration of CPAP
and BPAP in patients with Obstructive Sleep Apnea.18 Recom-
modation 4.7.2 is made with the understanding that pulse
oximetry can overestimate the actual arterial oxyhemoglobin saturation in some circumstances and that the effective inspired oxygen concentration can fall if machine flow increases due to higher leak.\textsuperscript{87-90} A slightly higher goal than 88% (90%-94%) might be prudent in some circumstances. Of note, since the intentional leak increases with the magnitudes of either IPAP or EPAP, the effective fraction of oxygen in the inspired air (FiO\textsubscript{2}) for a given supplemental oxygen flow rate (bleed in) falls as these pressures increase.\textsuperscript{87-90} The FiO\textsubscript{2} does not appear to vary with the amount of PS or the respiratory rate. Recommendation 4.7.4 is based on several studies of models that evaluated the optimal location at which supplemental oxygen should be connected to the NPPV circuit. A 3-orifice “T” shaped connector attached between the NPPV device outlet and the hose allows for the addition of supplemental oxygen into the circuit through the side arm of the T connector. The results of these studies varied somewhat possibly due to the position at which the FiO2 was sampled. One study found the best location to be at the NPPV outlet assuming the leak port was in the mask,\textsuperscript{89} while another found a connection midway between the machine and the exhalation valve\textsuperscript{87} was optimal. The latter attachment is not practical in most settings. In any case, an attachment position allowing adequate mixing and one providing a reservoir of enriched gas for inspiration appears to optimize the FiO\textsubscript{2} for a given supplemental oxygen flow and level of BPAP.

4.8 Recommendations Concerning Patient Comfort and Leak

4.8.1 If the patient awakens and complains that the IPAP, EPAP, or both pressures is (are) too high, the appropriate pressure(s) should be decreased to a lower pressure(s), chosen so that the patient reports a degree of comfort adequate to allow return to sleep. Elevation of the head of the bed (if not contraindicated) may be used as a strategy to allow down-titration of EPAP if the required pressure is difficult for the patient to tolerate. (Consensus)

4.8.2 Use of pressure relief during EPAP (flexible PAP) may improve patient comfort to a given level of EPAP if the patient complains of difficulty exhaling. This option is available only in the spontaneous mode in selected devices. (Level A - Consensus)

Recommendations 4.8.1 and 4.8.2 are based on consensus agreement by the NPPV titration task Force. Recommendation 4.8.1 is consistent with the AASM guidelines for titration of CPAP and BPAP in sleep apnea patients.\textsuperscript{48} Regarding 4.8.2, there is currently no evidence to support the use of pressure relief BPAP. To date, there is conflicting evidence about the ability of flexible CPAP to improve adherence.\textsuperscript{51,92} However, some patients may find flexible BPAP more comfortable. Pressure relief BPAP is available only in the spontaneous mode.

4.8.3 The rise time (time duration for pressure change from EPAP to set IPAP) should be increased or decreased for patient comfort. Patients with obstructive airway disease often prefer shorter rise times (100 ms to 400 ms) and patients with restrictive disease (NMD, RTCD) patients often prefer longer rise times (300 ms to 600 ms). A rise time of approximately 200 ms is usually the default on NPPV devices. (Level A - Consensus)

This recommendation is based on consensus of the task force. Adjustment of the rise time may improve patient tolerance to NPPV in certain patients. Typical rise times vary from 100 to 600 milliseconds.

4.8.4 Minimum IPAP duration (if available) maybe increased if the device cycles from IPAP to EPAP prematurely (e.g., in restrictive chest wall disorders). The maximum IPAP duration (if available) may be decreased if the device cycles to EPAP too late for patient comfort/synchrony (e.g., when mask leak is excessive). (Level A - Consensus)

Recommendation 4.8.4 is based on consensus agreement by the NPPV titration task force. NPPV devices transition from IPAP to EPAP during a patient triggered breath when flow falls below a set value. In patients with a stiff chest wall (decreased compliance), flow rates may fall as the maximum inspiratory volume is approached. An early fall in the absolute flow rates may trigger the transition to EPAP prematurely. Certain devices provide a minimum IPAP time to ensure that IPAP lasts long enough to allow delivery of an adequate tidal volume. In situations of high leak (continued flow) or muscle weakness, the IPAP to EPAP transition may be unduly delayed. A default maximum IPAP duration of 3 seconds exists on some devices, while in other devices a shorter maximal IPAP time may be chosen.

4.8.5 During the NPPV titration, mask refit, adjustment, or change in mask type should be performed whenever any significant unintentional leak is observed or the patient complains of mask discomfort. If mouth leak is present and is causing significant symptoms (arousals) use of an oronasal mask or chin strap can be tried. (Level A - Consensus)

4.8.6 In general, an unacceptable leak for NPPV at a given IPAP/EPAP is one that is significantly higher than the leak resulting from a given mask fitted securely in place at the current pressure settings. The expected value of leak will depend on the pressures, specific interface, and NPPV device (whether total or unintentional leak information is provided) as specified by the manufacturer. (Level A - Consensus)

The recommendations 4.8.5 and 4.8.6 are based on consensus agreement by the NPPV Titration Task Force and are consistent with the recommendations concerning leak in the Clinical Guidelines for Titration of PAP in patients with OSA.\textsuperscript{48} The total leak is equal to the sum of the intentional leak (required to prevent rebreathing) and unintentional leak (mask and/or mouth leak depending on whether a nasal or full face mask is being used). The intentional leak depends on the specific interface and the level of pressure. Intentional leak can be appreciable with most interfaces at high pressure. NPPV devices used in sleep centers provide an estimate of leak. Some devices allow specification of an interface type and adjust the reported leak values accordingly. The trend in leak is often more informative than the absolute leak value. For example, a sudden increase in leak with minor or no changes in treatment pressure is a hint that an increase in unintentional leak has occurred. Mask leak may be minimized by mask refit or readjustment and/or switch to another mask type. If mouth leak is suspected, use
of a chin strap or switch to a full face mask may be beneficial. Mouth leak is a significant problem in patients on NPPV treatment and may cause arousals even if the NPPV device is able to maintain the desired IPAP and EPAP.64-66 Teschler and coworkers65 studied a group of patient being treated with nasal BPAP who complained of symptomatic mouth leak. Taping the mouth substantially reduced arousals and increased the amount of REM sleep. Substantial mouth leak is often associated with complaints of oral dryness that may persist despite the use of heated humidification.

Although BPAP devices are leak tolerant, high leak can reduce the ability of a given pressure support setting to augment tidal volume.65,66 If tidal volume is inadequate and leak relatively high, interventions to reduce leak may improve tidal volume without requiring an increase in pressure support.

4.9 Recommendations for Grading the Quality of an NPPV Titration, Indications for Repeating a Titration, and Recommendations for Follow-up

4.9.1 Recommendations for grading the quality of an NPPV titration

4.9.1.1 The NPPV device settings used for treatment should ideally reflect the following treatment goals: Control of airway obstruction as defined by a respiratory disturbance index (RDI) < 5/hour, absence of snoring, a minimum \( \text{SpO}_2 > 90\% \) at sea level, normalization/improvement of ventilation with a PCO\(_2\) (if measured) no greater than 10 mm Hg above the treatment goal, reduction in excessive respiratory muscle activity, and a mask leak within acceptable parameters for the selected pressures and mask interface. In this work RDI refers to the number of apneas + hypopneas + RERAs and the hours of sleep. (Level A - Consensus)

4.9.1.2 An optimal titration meets the above treatment goals at the selected NPPV settings for at least a 15-minute period that includes REM sleep in the supine position (unless this position is contraindicated) that is not continually interrupted by arousals. (Level A - Consensus)

4.9.1.3 A good titration meets the above treatment goals at the selected NPPV settings for at least a 15-minute period that includes NREM sleep in the supine position (unless this position is contraindicated) and REM sleep in any position at the selected settings. (Consensus B)

4.9.1.4 An adequate titration meets the above treatment goals, except that the RDI must be less than 10/hour at the selected NPPV settings for at least a 15-minute period that includes NREM sleep in the supine position (unless this position is contraindicated) and REM sleep in any position at the selected settings. (Level A - Consensus)

4.9.1.5 An unacceptable titration is one that does not meet any one of the above standards. (Level A - Consensus)

The recommendations 4.9.1.1 to 4.9.1.5 are based on consensus of the NPPV titration task force and are similar to the grading of an adequate PAP titration in the clinical guidelines for PAP titration in patients with OSA.48 This scheme was based on grading criteria proposed by Hirshkowitz and Sharafkhaneh.93 It is acknowledged that the above grading scheme may not be relevant for all patients and must be individualized. For example, if the major goal of NPPV treatment is palliation, an optimal titration may well consist of NPPV settings that significantly improve patient comfort. Finally, since the technologies used for assessment of ventilation and/or respiratory muscle activity varies considerably among sleep laboratories, the task force offers solely what it deemed reasonable treatment goals for said parameters. Adequacy in these parameters should be defined individually by each sleep laboratory.

4.9.2 Indications for repeating an NPPV titration

4.9.2.1 A repeat NPPV titration study should be performed (if clinically indicated) when the initial titration does not achieve a grade of optimal, good, or adequate based on the above criteria, or if less than 3 hours of sleep was recorded during the titration. The decision to repeat the titration depends on the tolerance of the patient to NPPV and the clinical status and prognosis of the patient. (Level A - Consensus)

4.9.2.2. A repeat NPPV titration study should be considered if the respiratory function or sleep quality of a patient on chronic NPPV treatment deteriorates. Factors to consider include prognosis of the underlying disease process and the ability of the patient to adhere to NPPV treatment. (Level A - Consensus)

Recommendations 4.9.2.1 and 4.9.2.2 are based on consensus. The clinician must consider the long-term prognosis and tolerance of the patient to both NPPV titration with PSG and NPPV treatment. A similar grading scheme was presented in the AASM clinical guidelines for the titration of CPAP and BPAP in sleep apnea patients.48

4.9.3 Recommendations for follow-up after NPPV titration

4.9.3.1 Before treatment is started, the durable medical equipment company should educate the patient and caregiver about device parts and assembly, optional equipment, the importance of daily/nightly use, adherence issues, necessity of, and techniques for, cleaning the equipment, and implications of the purchase/rental of the equipment (when applicable). (Level A - Consensus)

4.9.3.2 Close follow-up after initiation of NPPV by appropriately trained health care providers is indicated to establish effective utilization patterns (ideally using objective adherence data), remediate problems including NPPV side effects and interface issues, and ensure that the equipment is maintained in good repair and disposable equipment is changed on a regular schedule as clinically indicated. (Level A - Consensus)

Recommendations 4.9.3.1 and 4.9.3.2 are based on consensus of the task force and are consistent with recommendations made in the clinical guidelines for titration of CPAP and BPAP in patients with OSA.48 Minimal information is available concerning adherence to NPPV treatment except for patients...


ACKNOWLEDGMENTS

This report could not have been completed without the administrative support of the American Academy of Sleep Medicine, specifically, Jerome A. Barret, Jennifer Markkanen, and Jordana Money.

SUBMISSION & CORRESPONDENCE INFORMATION

Submitted for publication August, 2010
Accepted for publication August, 2010
Address correspondence to: Richard B. Berry, M.D., Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Box 100225 HSC, University of Florida, Gainesville, Florida 32610-0225

DISCLOSURE STATEMENT

This was not an industry supported study. The authors have indicated no financial conflicts of interest.
### Appendix

<table>
<thead>
<tr>
<th>First Author Reference</th>
<th>Disorder/ Patient No.</th>
<th>Design</th>
<th>Titration</th>
<th>Equipment/ Pressure</th>
<th>Outcome/Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambrogio(^9) 2009</td>
<td>Chronic hypercapnic respiratory failure using NPPV</td>
<td>Randomized Crossover Level I</td>
<td>BPAP titration with PSG start BPAP = 8/4, titrate to eliminate obstructive events (apnea, hypop, FL)</td>
<td>AVAPS IPAPmax = 30 or IPAP chosen for IPAP-T + 10 IPAPmin = IPAP-T - 5 AVAPS tidal volume goal either 8 ccc/kg or 110% of calm tidal breathing (patient preference)</td>
<td>Equivalent sleep quality on AVAPS and BPAP Higher minute ventilation on AVAPS</td>
</tr>
<tr>
<td></td>
<td>OHS (with/ without OSA) COPD NMD</td>
<td>N = 28</td>
<td>3 PSGs <strong>1. Prescription-Validation</strong> BPAP titration to validate chronic NPPV settings</td>
<td><strong>IPAP-T = chosen IPAP level from BPAP titration</strong></td>
<td><strong>2. AVAPS or BPAP treatment</strong> <strong>3. Crossover to alternate treatment</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Outcome/Findings</strong></td>
<td><strong>Evidence Level</strong></td>
<td><strong>Design</strong></td>
<td><strong>Titration</strong></td>
<td><strong>Equipment/ Pressure</strong></td>
</tr>
<tr>
<td>Ambrogio(^9) 2009</td>
<td><strong>Disorder/ Patient No.</strong></td>
<td><strong>Evidence Level</strong></td>
<td><strong>Design</strong></td>
<td><strong>Titration</strong></td>
<td><strong>Equipment/ Pressure</strong></td>
</tr>
<tr>
<td>Banerjee(^7) 2007</td>
<td>Prospective study of patients with BMI ≥ 50kg/m(^2) undergoing PSG group 1: OSA (AHI &gt; 15/hr) N =23 group 2: OSA+ OHS = OSA + PCO(_2) &gt; 45 mmHg without lung disease N = 23</td>
<td><strong>Level IV</strong></td>
<td>PSG #1 Diagnostic, if AHI ≥ 15/hr then CPAP PSG 2(^\text{nd}) PSG with CPAP measurements during CPAP trial</td>
<td>Manual PSG CPAP titration with auto-CPAP device CPAP titrated to normalize inspiratory flow pattern Once flow trace had normalized CPAP was increased by no more than 3 cm H(_2)O in attempt to improve SaO(_2)</td>
<td><strong>Outcome/Findings</strong> <strong>Evidence Level</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Evidence Level</strong></td>
<td><strong>Design</strong></td>
<td><strong>Titration</strong></td>
<td><strong>Equipment/ Pressure</strong></td>
<td></td>
</tr>
<tr>
<td>Berger(^3) 2001</td>
<td>OHS 49 retrospectively identified 23 came for follow-up</td>
<td><strong>Level IV</strong></td>
<td>PSG for Dx PSG for PAP titration -- &gt; ultimate Rx depends on response to CPAP during the titration group 1 treated with CPAP group 2 treated with BPAP</td>
<td>PSG titration: 1. CPAP increased to eliminate obstructive events 2. If SaO(_2) &lt; 90% + flow limitation, CPAP increased If effective --&gt; group 1: CPAP Rx (noncompliant had trach) 3. If SaO(_2) &lt; 90% when no Flow limitation: group 2 BPAP used (noncompliant had trach + volume vent)</td>
<td><strong>Outcome/Findings</strong> <strong>Evidence Level</strong></td>
</tr>
</tbody>
</table>

Continues on following page
<table>
<thead>
<tr>
<th>First Author Reference</th>
<th>Evidence Level</th>
<th>Disorder/ Patient No.</th>
<th>Design</th>
<th>Titration</th>
<th>Equipment/ Pressure</th>
<th>Outcome/Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bourke 2003</td>
<td>ALS patients</td>
<td>ALS group followed</td>
<td>NPPV started in Hospital</td>
<td>nasal, oro-nasal, total face masks, mouthpieces</td>
<td>NPPV associated with improved quality of life</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quality of life measures every 2 months</td>
<td>BPAP adjusted on basis of nocturnal oximetry and daytime ABGs, + compliance</td>
<td>Survival correlated with compliance to NPPV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PSG every 4 months in group with ALS</td>
<td>15 tried NPPV</td>
<td>IPAP = 16</td>
<td>orthopnea best indicator of benefit from NPPV and adherence (better than AHI, nocturnal symptoms, PCO₂)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Those meeting criteria were offered NPPV</td>
<td>10 continued NPPV</td>
<td>EPAP = 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Analysis: comparison of Pre-NPPV measures with post-NPPV measures</td>
<td>Backup rate not specified</td>
<td>Asynchrony due to leaks controlled by limiting IPAP max</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bourke 2006</td>
<td>ALS patients</td>
<td>ALS patients randomized to standard care or NPPV</td>
<td>NPPV started in hospital</td>
<td>VPAP ST II</td>
<td>Compared to standard care, NPPV improved survival and quality of life in the subgroup with better bulbar function</td>
<td></td>
</tr>
<tr>
<td>Lancet Neuro</td>
<td></td>
<td>baseline PSG at randomization AHI not specified “some obstr events during REM sleep”</td>
<td>Settings adjusted using daytime ABG, nocturnal oximetry, and NPPV use</td>
<td>ST mode (backup rate not specified nasal, oronasal, oral masks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td></td>
<td>Goal = normal daytime arterial blood gas</td>
<td></td>
<td>IPAP mean 15</td>
<td>Bulb group – NPPV may improve nocturnal symptoms but not survival</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>quality of life measures</td>
<td></td>
<td>EPAP mean 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SALQI</td>
<td></td>
<td>IPAP max =24</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EPAP max = 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budweiser 2006</td>
<td>RTCD</td>
<td>Testing during day after NPPV treatment</td>
<td>NPPV started in hospital</td>
<td>nasal or full face mask</td>
<td>Improvements in daytime PCO₂, PO₂, lung volumes, and muscle strength</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N = 62 initial</td>
<td>Variable treatment duration but &gt; 3.8 months</td>
<td>Adaptation phase</td>
<td>Pressure NPPV ST mode</td>
<td>changes in daytime PCO₂ was not correlated with duration of use.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N = 44 patients</td>
<td></td>
<td>NPPV gradually increased</td>
<td>IPAP = 21.1 ± 3.4</td>
<td>Improvements in daytime vital capacity (VC) correlated with IPAP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>available for analysis</td>
<td></td>
<td>ABG measured twice at night 01:00 AM and 04:00 AM</td>
<td>EPAP = 3.1 ± 2.3</td>
<td>Reduction in daytime PCO₂ correlated with PS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NPPV goals: target tidal volume= 10 cc/kg</td>
<td>PS = 18 ± 3.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>reduction in PCO₂ 10-15%</td>
<td>mean respiratory rate = 20.6 bpm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Heated humidification if dryness</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budweiser 2007</td>
<td>OHS</td>
<td>PSG documents OHS</td>
<td>NPPV started in hospital</td>
<td>nasal or full face masks</td>
<td>Daytime PCO₂ decreased</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N =126</td>
<td>OHS 87 patients, (69%) had OSA</td>
<td>Pressure NPPV ST mode</td>
<td>BPAP ST</td>
<td>Adherence (mean) = 6.5 hrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PCO₂ ≥ 45 mm Hg</td>
<td>NPPV treatment then--&gt; 118 re-evaluated in hospital at 3 to 6 months with daytime and nighttime ABG</td>
<td>IPAP increased with goal of reaching a tidal volume of 10 cc/kg ideal body weight</td>
<td>IPAP 22.5 ± 3.6 mbar</td>
<td>PCO₂ changed</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oxygen added only after PS optimized to achieve SaO₂ &gt; 90%</td>
<td>backup rate 19.2/min</td>
<td>EPAP 5.8 ± 3.1 mbar</td>
<td>Daytime 55.5 --&gt; 42.1 mmHg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nighttime 59.0 --&gt; 44.7 mmHg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1, 2, 5 year survival</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>97%, 92%, 70% all cause-mortality</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continues on following page
<table>
<thead>
<tr>
<th>First Author Reference</th>
<th>Disorder / Patient No.</th>
<th>Design</th>
<th>Titration</th>
<th>Equipment / Pressure</th>
<th>Outcome / Findings (abbreviations at end of table)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chatwin&lt;sup&gt;6&lt;/sup&gt; 2008</td>
<td>N = 28 RTCD and NMD Patients with nocturnal hypoventilation</td>
<td>NPPV started in PSG after 2 months of treatment at home</td>
<td>Inpatient – stay sufficient for patient competence</td>
<td>Pressure preset NPPV Starting settings: Peak insp pressure 16 cm H&lt;sub&gt;2&lt;/sub&gt;O and backup rate 15-20 bpm</td>
<td>Improvements in nocturnal SpO&lt;sub&gt;2&lt;/sub&gt; similar in both groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td>After 2 months in hospital overnight monitoring of SpO&lt;sub&gt;2&lt;/sub&gt; and transcutaneous PCO&lt;sub&gt;2&lt;/sub&gt;, as well as daytime ABG</td>
<td>Outpatient – 3 visits</td>
<td>Nasal masks used if possible, full face if mouth leak</td>
<td>Peak nocturnal transcutaneous PCO&lt;sub&gt;2&lt;/sub&gt; improved in both groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Baseline daytime PCO&lt;sub&gt;2&lt;/sub&gt; in both groups 44.2 mmHg (inpatient) and 45.7 (outpatient)</td>
<td>Outpatient – patient needed an adjustments made to achieve “good” tidal volume</td>
<td>Daytime PCO&lt;sub&gt;2&lt;/sub&gt; decreased in outpatient group</td>
<td>Conclusion: outpatient initiation of home ventilation is feasible</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Baseline peak nocturnal transcutaneous PCO&lt;sub&gt;2&lt;/sub&gt;: 75 mmHg in outpatient, 71.2 inpatient group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Lucas-Ramos&lt;sup&gt;19&lt;/sup&gt; 2004</td>
<td>OHS N = 13 non-consecutive patients</td>
<td>type 3: Home Sleep Testing at baseline 12 mo of NPPV At baseline and after 12 mo NPPV treatment, overnight oximetry, respiratory muscle strength, and mouth occlusion pressure tested</td>
<td>NPPV started in hospital daytime 2 hr adaptation period</td>
<td>BPAP Nasal mask used end IPAP = 19 ± 2 EPAP of 5 cm H&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>NPPV→ improved daytime PCO&lt;sub&gt;2&lt;/sub&gt;, PO&lt;sub&gt;2&lt;/sub&gt;, FVC, and the mouth occlusion pressure responses to hypercapnia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Initial pressure IPAP = 16, EPAP = 5 then IPAP adjusted during daytime based on arterial blood gas. Nocturnal treatment started IPAP, EPAP</td>
<td></td>
<td>9/13 needed supplemental oxygen</td>
</tr>
<tr>
<td>Ellis&lt;sup&gt;23&lt;/sup&gt; 1988</td>
<td>RTCD KS (N = 7)</td>
<td>PSG before and after Rx using Transcutaneous PCO&lt;sub&gt;2&lt;/sub&gt; (snoring, ob apn found) 3 months of treatment</td>
<td>Titration method not specified</td>
<td>nasal mask 5 NPPV (volume cycled) 2 CPAP</td>
<td>NPPV improved sleep quality with lower nocturnal PtCO&lt;sub&gt;2&lt;/sub&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Daytime: NPPV increased respiratory muscle strength, improved ABGs, improved lung volumes</td>
</tr>
<tr>
<td>Gonzalez&lt;sup&gt;24&lt;/sup&gt; 2003</td>
<td>RTCD N = 16</td>
<td>1. Baseline PSG 2. NPPV treatment for 36 months 3. At 6 mo PSG OFF NPPV Other outcomes monitored over 3 years</td>
<td>NPPV started in hospital (Respiratory Care Unit) Adaptation to NPPV during 2-3 hrs in the morning mask, mode settings based on comfort, SaO&lt;sub&gt;2&lt;/sub&gt;, PtCO&lt;sub&gt;2&lt;/sub&gt; then→ 2 - 3 nights with adjustment of settings based on SaO&lt;sub&gt;2&lt;/sub&gt;, PtCO&lt;sub&gt;2&lt;/sub&gt; Goal: PCO&lt;sub&gt;2&lt;/sub&gt; ≤ 45 mmHg SaO&lt;sub&gt;2&lt;/sub&gt; &gt; 90 % either volume vent or BPAP FIO&lt;sub&gt;2&lt;/sub&gt; increased if goals not met</td>
<td>Volume cycled NPPV in 7 Pressure cycled NPPV in 9 nasal mask 12, FFM 4 BPAP ST mode IPAP 15 to 22 cm H&lt;sub&gt;2&lt;/sub&gt;O EPAP 4 mean IPAP = 15 ± 2.8 backup rate 15 bpm Volume vent: Tidal volume = 10-15 cc/kg BF 15-25</td>
<td>Before NPPV PSG AHI = 13.9 After NPPV treatment, PSG (off NPPV) AHI =12.9 SaO&lt;sub&gt;2&lt;/sub&gt; improved at night but not sleep efficiency \hspace{1cm} \text{Daytime PO}_2, FVC, Resp Muscle strength improved at 36 mo \hspace{1cm} \text{Less hospitalizations} \hspace{1cm} \text{Supplemental O}_2 at 11pm in 6 patients</td>
</tr>
</tbody>
</table>

Continues on following page
<table>
<thead>
<tr>
<th>First Author Reference Evidence Level</th>
<th>Disorder/ Patient No.</th>
<th>Design</th>
<th>Titration</th>
<th>Equipment/ Pressure</th>
<th>Outcome/Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gruis et al. 2006 retrospective</td>
<td>NMD 55 total</td>
<td>Started NPPV</td>
<td>NPPV started as out patient</td>
<td>Nasal prongs (Nasal Aire) interface</td>
<td>18 tolerated NPPV</td>
</tr>
<tr>
<td></td>
<td>18 tolerated NPPV</td>
<td>Patients followed</td>
<td>Initial: NPPV 8/3 cm H&lt;sub&gt;2&lt;/sub&gt;O - changes based on symptoms</td>
<td>Only 6/18 (33%) required PS &gt; 10 cm H&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>4 used 8/3 cm H&lt;sub&gt;2&lt;/sub&gt;O until death</td>
</tr>
<tr>
<td></td>
<td>19 intolerant</td>
<td>classified as NPPV tolerant if &gt; 4 hrs use (subjective) at follow-up visits</td>
<td>- most pressure changes occurred in the first year</td>
<td>3 ALS has symptoms of OSA</td>
<td>Max pressure 19/5 cm H&lt;sub&gt;2&lt;/sub&gt;O</td>
</tr>
<tr>
<td></td>
<td>followed</td>
<td>3 of 18 NPPV tolerant patients had symptoms of OSA</td>
<td>IPAP increased in 2 cm H&lt;sub&gt;2&lt;/sub&gt;O increments until symptoms improved</td>
<td>PSG found 2 had OSA</td>
<td>patients with different numbers of pressure changes “for comfort”</td>
</tr>
<tr>
<td></td>
<td>classified as NPPV</td>
<td>2 of 18 NPPV tolerant patients diagnosed with PSG</td>
<td></td>
<td></td>
<td>N = 4 no change</td>
</tr>
<tr>
<td></td>
<td>tolerant if &gt; 4 hrs</td>
<td>use (subjective) at follow-up visits</td>
<td></td>
<td></td>
<td>8 single change</td>
</tr>
<tr>
<td></td>
<td>use (subjective)</td>
<td>at follow-up visits</td>
<td></td>
<td></td>
<td>4 two changes</td>
</tr>
<tr>
<td></td>
<td>at follow-up visits</td>
<td></td>
<td></td>
<td></td>
<td>1 three changes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 five changes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>patients tolerating NPPV had longer survival</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guilleminault et al. 1998</td>
<td>NMD Muscular dystrophy and others</td>
<td>1. PSG for diagnosis + MSLT</td>
<td>PSG for BPAP titration</td>
<td>BPAP S (N = 18)</td>
<td>Mean RDI 28.2/hr (8.9); 78% central apnea</td>
</tr>
<tr>
<td>Case Series</td>
<td>N = 20</td>
<td>2. PSG for BPAP titration</td>
<td>Titratiion goal: eliminate apnea, hypopnea, hypoventilation</td>
<td>BPAP T (N =1)</td>
<td>19 /20 accepted NPPV</td>
</tr>
<tr>
<td>Level IV</td>
<td></td>
<td>3. 4wks NPPV Rx</td>
<td></td>
<td>EPAP 5 cm H&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>Mean Sleep latency (MSLT) increased after NPPV treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4. PSS on NPPV + MSLT</td>
<td></td>
<td>IPAP 11.5 (9 to 14) cm H&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>MSL increased from 8.2 minutes to 12 minutes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3 switched to volume ventilators</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guo et al. 2007</td>
<td>OHS Using NPPV for at least 3 months</td>
<td>PSG during NPPV in patients on chronic NPPV treatment</td>
<td>PSG on NPPV while monitoring machine pressure, mask pressure, airflow, transcutaneous PCO&lt;sub&gt;2&lt;/sub&gt;</td>
<td>nasal (17) or full face masks (3), 4 also on supplemental oxygen</td>
<td>55% had desynchronization</td>
</tr>
<tr>
<td>Level IV</td>
<td>N = 20</td>
<td></td>
<td>Note transcutaneous CO&lt;sub&gt;2&lt;/sub&gt; device calibrated with calibration gas before each measurement night</td>
<td>BPAP ST mode used</td>
<td>40% frequent periodic breathing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mean IPAP = 18.5 ± 4.6</td>
<td>auto-triggering uncommon but frequent in a single patient</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mean EPAP = 6.2 ± 1.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mean backup rate = 13.7 ± 2.2 bpm</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janssens et al. 2008</td>
<td>OHS stable on chronic NPPV</td>
<td>NPPV using current settings</td>
<td>no titration</td>
<td>9 FFM, 3 nasal masks</td>
<td>mean tidal volume, ventilation, IPAP higher with VT-BPAP – all small differences</td>
</tr>
<tr>
<td>assess effect of volume targeted BPAP on sleep quality</td>
<td>N = 12</td>
<td>one night and VT-BPAP on the other night</td>
<td>studied at current settings</td>
<td>ST mode</td>
<td>Slight improvement in nocturnal PCO&lt;sub&gt;2&lt;/sub&gt; on VT-BPAP compared BPAP</td>
</tr>
<tr>
<td>Randomized cross over</td>
<td>PSG with Ptc CO&lt;sub&gt;2&lt;/sub&gt;</td>
<td>chronic settings (cmH&lt;sub&gt;2&lt;/sub&gt;O): IPAP = 21.6 ± 4.7</td>
<td>VT 7.8 cc/kg</td>
<td>IPAP&lt;sub&gt;min&lt;/sub&gt; = 30 cm H&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>amounts of stage N2 and TST better with BPAP than VT-BPAP</td>
</tr>
<tr>
<td>Level II for VT-BPAP</td>
<td>VT-BPAP adjusted during day to find tolerated settings</td>
<td>EPAP 8.6 ± 2.7</td>
<td>IPAP&lt;sub&gt;min&lt;/sub&gt; = usual IPAP – 3</td>
<td>usual IPAP – 3</td>
<td>Better subjective sleep quality on BPAP</td>
</tr>
<tr>
<td></td>
<td>backup rate 13.3 ± 2.0 range (10-17) bpm</td>
<td></td>
<td>Backup rate same as chronic treatment</td>
<td></td>
<td>WASO higher with VT-BPAP</td>
</tr>
<tr>
<td></td>
<td>backup rate 13.3 ± 2.0 range (10-17) bpm</td>
<td></td>
<td></td>
<td></td>
<td>critique = lack of adaptation to VT-BPAP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Katz et al. 2002</td>
<td>children NMD</td>
<td>PSG for Diagnosis</td>
<td>NPPV titration with PSG</td>
<td>nasal mask</td>
<td>Post NPPV initiation</td>
</tr>
<tr>
<td>Case Series</td>
<td>Spinal muscular atrophy, DMD, myotonic dystrophy, myopathies</td>
<td>PSG baseline AHI = 7.3/hour</td>
<td>PtcCO&lt;sub&gt;2&lt;/sub&gt; used</td>
<td>nasal pillows</td>
<td>children spent 85% fewer days in hospital</td>
</tr>
<tr>
<td>Level IV</td>
<td>N = 15</td>
<td>PSG for BPAP titration</td>
<td>NPPV Goal: a decrease of at least 10 mmHg if PtcCO&lt;sub&gt;2&lt;/sub&gt; was &gt; 50 mmHg</td>
<td>IPAP 9 – 20 cm H&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>PtcCO&lt;sub&gt;2&lt;/sub&gt; repeated on NPPV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>then follow-up</td>
<td>normalize respirations and SaO&lt;sub&gt;2&lt;/sub&gt;</td>
<td>EPAP 3-6</td>
<td>Nocturnal PtcCO&lt;sub&gt;2&lt;/sub&gt; normalized AHI decreased</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In 9 PSG repeated at follow-up</td>
<td></td>
<td>backup rate set at 10% below resting breathing rate</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continues on following page
<table>
<thead>
<tr>
<th>First Author Reference Evidence Level</th>
<th>Disorder/ Patient No.</th>
<th>Design</th>
<th>Titration</th>
<th>Equipment/ Pressure</th>
<th>Outcome/Findings (abbreviations at end of table)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leger²⁰ 1994 Case Series Level IV</td>
<td>Mixed population with CAH KS post TB sequelae MD COPD N = 276</td>
<td>NPPV started in hospital after exacerbation Long term flu</td>
<td>NPPV started in hospital after exacerbation Titration details not specified Humidity in 1/3</td>
<td>customized nasal masks volume ventilation 12=15cc/kg tidal volume assist-control or control mode breaths per minute 15 to 16</td>
<td>KS, post TB improved quality of life and daytime gas exchange, less hospital days MD – less continued NPPV, did reduce hospital days Side effects dryness, gastric distension, nasal congestion, eye irritation, nasal bridge soreness</td>
</tr>
<tr>
<td>Masa¹⁶ 2001 Crossover trial not randomized order Level II</td>
<td>OHS N =22 PCO₂ &gt; 47 RTCD (KS) N = 14 PCO₂ &gt; 47</td>
<td>PSG, if AHI &lt; 20/hr admitted to hospital for protocol re-evaluation after 4 months of NPPV</td>
<td>NPPV started in hospital Titration details not provided Adaptation to NPPV 3 to 7 days Goal: maximal reduction in PCO₂, and maintenance of SaO₂ &gt; 90%. 11 OHS, 8 KS required oxygen supplement at start of study -&gt; at end only 2 OHS using supplemental oxygen at night</td>
<td>Volume cycled ventilator in most, BPAP in 5 OHS, 1 KS</td>
<td>OHS group daytime PCO₂ decreased from 58 to 45 mmHg RTCD group: daytime PCO₂ decreased from 59 to 45 mmHg after treatment, no change in muscle strength or PFTs Both OHS and RTCD had equivalent improvement in symptoms and daytime gas exchange with NPPV treatment Conclusion: NPPV effective in OHS</td>
</tr>
<tr>
<td>Masa¹¹ 1997 Oxygen vs NPPV Crossover trial Level II</td>
<td>RTCD 8 7KS+1 thoracoplasty 2 NMD 11 OHS No daytime hypercapnia. 27 nocturnal desaturators without OSA 21 completed the protocol</td>
<td>baseline PSG to demonstrate desaturation without OSA RTCD patients had AHI 5.6/hour overall but 19 ± 17/hour during REM sleep. 2 wks of nocturnal oxygen then PSG on oxygen then 2 wks nocturnal NPPV then PSG on NPPV</td>
<td>NPPV started in hospital Adaptation period 3 to 7 days. The protocol was not specified</td>
<td>BPA P N = 7 Volume cycled ventilator N=20</td>
<td>NPPV not oxygen normalized nocturnal hypoventilation and improved symptoms oxygen treatment had greater nocturnal saturation Daytime PO₂ improved only after NPPPV Conclusion: RTCD patients without daytime hyperventilation but with nocturnal hyperventilation and desaturation obtain more benefit from NPPV than nocturnal oxygen</td>
</tr>
<tr>
<td>Melies²⁴ 2003 Case Series Level IV</td>
<td>NMD children N = 30</td>
<td>1. PSG for dx 2. PSG for titration 3. Follow-up RDI 10.5 ± 13.1 REM RDI 20.5 ±21.1</td>
<td>NPPV titration using PSG BPAP ST mode goals: suppress SDB, SaO₂ &gt; 95%, PtCO₂ &lt; 50 mmHg PetCO₂ used, calibrated before each study</td>
<td>Full face mask (10) nasal masks, others IPAP 13.9 range (8-19) EPAP 4.4 range (3-8) backup rate 19.6 (14-24) bpm</td>
<td>Improvement in daytime PCO₂ and PO₂ Improvement in TST with PCO₂ &gt; 50 or TST with SaO₂ &lt; 90%</td>
</tr>
<tr>
<td>Perez de Llano²² 2005 Retrospective Study Case Series Level IV</td>
<td>OHS started on NPPV 20 elective 34 after exacerbation</td>
<td>NPPV treatment then follow-up PSG performed once stable and discharged from the hospital</td>
<td>NPPV started in hospital PSG not used for titration daytime sessions for exacerbations night time session for all starting EPAP=6 cmH₂O IPAP=10 titrated upward adjusted based on nocturnal SaO₂ PIP &gt; 20 poorly tolerated nasal mask</td>
<td>At discharge: N=3 CPAP N=2 vol vent N=49 BPAP mean IPAP=18 (12-30) mean EPAP = 9 (5-13) N=47 needed supplemental oxygen</td>
<td>AHI &gt; 5 in 87% 47% required supplemental oxygen ESS decreased from 16 to 6 mean decrease in daytime PCO₂ was 17 mmHg PCO₂ fell after discharge from hospital on treatment: not necessary to totally normalize PCO₂ — continued improvement occurs over time</td>
</tr>
</tbody>
</table>

Continues on following page
<table>
<thead>
<tr>
<th>First Author Reference</th>
<th>Disorder/ Patient No.</th>
<th>Design</th>
<th>Titration</th>
<th>Equipment/ Pressure</th>
<th>Outcome/Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perez de Llano(^1^) 2008 Level IV</td>
<td>OHS N = 24 N=11 CPAP N=13 NPPV</td>
<td>OHS stabilized on NPPV</td>
<td>NPPV titration by PSG CPAP used to eliminate obstructive events. If low SaO(_2) persisted BPAP used EPAP = CPAP and IPAP increased up to 20 to improve SaO(_2). If not effective supplemental oxygen was added</td>
<td>CPAP group mean pressure 10.4 cm H(_2)O NPPV group 11 BPAP, 2 volume vent. Pressures not presented</td>
<td>CPAP group had higher AHI and worse SaO(_2). NPPV group had lower AHI and worse SaO(_2).</td>
</tr>
<tr>
<td>Piper and Sullivan(^6^) 1996 Does NPPV at night improve spontaneous ventilation during sleep (i.e., NPPV)? Case Series Level IV</td>
<td>NMD 8 RTCD 6 N = 14</td>
<td>1. Baseline PSG before 2. 6 mo NPPV treatment 3. Sleep study OFF NPPV after 6 mo or greater treatment.</td>
<td>NPPV started in hospital NPPV protocol not clearly specified, NPPV adjusted based on patient tolerance, adjusted with nocturnal oximetry NPPV settings verified by PSG before discharge</td>
<td>nasal mask 13 patients volume ventilator 1 patient pressure ventilator</td>
<td>Daytime Chronic NPPV improved spontaneous daytime PO(_2) and PCO(_2) and muscle strength Night time: chronic NPPV improved nocturnal SaO(_2) and transcutaneous PCO(_2) during sleep (off treatment)</td>
</tr>
<tr>
<td>Piper(^2^2) 2007 RCT Level I CPAP vs BPAP</td>
<td>OHS stable awake PCO(_2) &gt; 45, pH &gt; 7.34 18 CPAP 16 BPAP</td>
<td>Initial CPAP trial in all subjects -- excluded those with persistent nocturnal hypoxemia or CO(_2) retention despite CPAP those on BPAP had an additional PSG for BPAP titration compared long term rx with CPAP versus BPAP over 3 months</td>
<td>NPPV titration with PSG starting EPAP = effective CPAP -2 (minimum 5) starting IPAP such that PS =4. EPAP increased in 1 cm H(_2)O increments if inspiratory efforts did not trigger IPAP IPAP increased to eliminate hypopneas and improve SaO(_2)</td>
<td>CPAP mean pressure was 14 cm H(_2)O BPAP S mode mean IPAP = 16 cm H(_2)O EPAP = 10 cm H(_2)O 7 patients on supplemental oxygen</td>
<td>Both groups decrease in daytime PCO(_2) – no difference between CPAP and BPAP Similar improvements in ESS, PVT, Adherence</td>
</tr>
<tr>
<td>Redolfi(^2^) 2006 Leptin in OHS prospective case controlled Level IV</td>
<td>OHS N = 6</td>
<td>1. Type 3 monitor used excluded OHS patients with OSA (AHI &gt; 5.hr) 2. Leptin before and after 10 months of NPPV 3. Results compared with 6 eucapnic obese subjects</td>
<td>Location where NPPV started is unclear (hospital or clinic?). EPAP =4 IPAP adjusted on basis of overnight oximetry until SaO(_2) &gt; 90%, if higher IPAP not tolerated supplemental oxygen was added Type 3 device on NPPV to evaluate settings.</td>
<td>BPAP Synchrony device mean pressures IPAP = 12 EPAP = 4</td>
<td>Daytime PO(_2) increased, PCO(_2) decreased leptin increased</td>
</tr>
</tbody>
</table>

Continues on following page
<table>
<thead>
<tr>
<th>First Author</th>
<th>Disorder/ Patient No.</th>
<th>Design</th>
<th>Titration</th>
<th>Equipment/ Pressure</th>
<th>Outcome/Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramesh</td>
<td>Congenital Central Hypoventilation Syndrome N = 15 age range 9 months to 21 years</td>
<td>9 patients started NPPV at later age 6 patients started NPPV at 5 to 26 weeks of age with positive pressure ventilation via endotrachal tube, 1 on positive pressure ventilation via tracheostomy</td>
<td>NPPV protocol not presented</td>
<td>nasal and face masks Details of pressures used not presented</td>
<td>NPPV started at later age took median of 3 years to wean from former mode of ventilation to mask ventilation</td>
</tr>
<tr>
<td>Simonds</td>
<td>NMD or RTCD N = 40 children 17 daytime resp failure 18 nocturnal hypoventilation 3 being weaned 2 frequent chest infections</td>
<td>overnight SaO₂, Ptc CO₂ monitoring, some had full PSG monitoring repeated once NPPV settings finalized</td>
<td>NPPV started in hospital NPPV settings determined by overnight SaO₂, PtcCO₂ monitoring, supplemental oxygen if needed</td>
<td>BPAP in ST mode 20 ffm, 18 nasal masks, 2 nasal pillows mean pressures not given</td>
<td>38 of 40 tolerated mask ventilation Nocturnal: peak PtcCO₂ decreased, mean and minimum PO₂ improved</td>
</tr>
<tr>
<td>Storre</td>
<td>OHS N = 10 &quot;Non-responders&quot; to CPAP 1. 6 weeks of AVAPS or BPAP-ST then PSG 2. 6 weeks of alternate mode then PSG</td>
<td>NPPV settings according to daytime and nighttime tolerance and to maximally decrease PtcCO₂</td>
<td>AVAPS IPAPmax = 30 mbar target volume 7 to 10 cc/kg BPAP ST IPAP up to 20 mbar EPAP 4 to 8 mbar both modes: backup rate = 12 to 18 bpm I/E 1 : 2</td>
<td>Sleep quality and oxygen saturation, quality of life equivalent between AVAPS and BPAP ST Daytime PCO₂ after 6 weeks slightly lower on AVAPS Nocturnal PtcCO₂ lower on AVAPS mean difference 6.9 mm Hg</td>
<td></td>
</tr>
<tr>
<td>Tibballs</td>
<td>Congenital Central Hypoventilation N = 4</td>
<td>2 newborns treated with nasal mask and BPAP when parents refused tracheostomy 2 older children transitioned trach / volume ventilator to nasal mask BPAP</td>
<td>Titration protocols not specified</td>
<td>Nasal masks Case #3 developed mid-face hypoplasia uses negative pressure ventilator most nights, for travel BPAP used Case #4 BPAP started at age 9 months, developed mid-face hypoplasia, at age 3 years used combination of BPAP to fall asleep and negative pressure ventilator for most of night</td>
<td>2 cases mid-face hypoplasia developed then switched to negative pressure ventilator for at least part of treatment maxilla may fail to grow in relation to mandible- lower jaw protrudes &quot;pseudoprognathism&quot;</td>
</tr>
</tbody>
</table>

Continues on following page
<table>
<thead>
<tr>
<th>First Author Reference Evidence Level</th>
<th>Disorder/ Patient No.</th>
<th>Design</th>
<th>Titration</th>
<th>Equipment/ Pressure</th>
<th>Outcome/ Findings (abbreviations at end of table)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toussaint77 2008 Prospective Case Series Level IV</td>
<td>NMD Duchenne muscular dystrophy group 1: no dyspnea, no support group 2: nocturnal hypercapnia group 3: nocturnal NPPV, no breathlessness group 4: nocturnal NPPV with breathlessness group 5 using 24 hr NPPV</td>
<td>group 4 nightly NPPV but no breathlessness TT0.1 tension time index a measure of muscle load measured at 20:00 and at 8:00 after NPPV</td>
<td>Not specified tidal volume 12 cc/kg then reduced slowly goal maintain normocapnia</td>
<td>NPPV Volume ventilator mean tidal volume 653 ml, mean RR 19.9</td>
<td>Tension time index higher with greater weakness group 1 to 3 not improvement in tension time index after overnight NPPV group 4 and 5 showed significant reduction in tension time index after overnight NPPV NPPV improved AM muscle function</td>
</tr>
<tr>
<td>Tuggey and Elliot27 2005 Randomized Crossover pressure versus volume ventilation Level II for type of NPPV</td>
<td>RTCD N = 13</td>
<td>Randomized crossover design after treatment for 4 weeks, PSG on NPPV with either pressure or volume mode Volume vs Pressure NPPV compared</td>
<td>No EPAP provided daytime titration either pressure or volume ventilation adjusted to give equivalent minute ventilation Volume ventilatory = tidal volume increased in 100 cc increments IPAP increased in increments of 5 cm H2O between limits of 10 and 40 cm</td>
<td>TV pressure/Volume to 548/546 Pressure mode backup rate =15 IPAP =25 cm H2O RR =15 Volume mode: backup rate 15 TV 749 ml</td>
<td>Night time: 2 modes provided equivalent sleep quality and SaO2 Daytime: 2 modes resulted in equivalent respiratory muscle strength, health status, ABGs, and daytime function Pressure NPPV showed more leak and lower ventilation Pressure and volume ventilation modes showed lower ventilation during sleep than wake titration</td>
</tr>
<tr>
<td>Tuggey73 2006 comparing titration goal of respiratory muscle rest and reverse nocturnal hypoventilation Level II for titration goal</td>
<td>N = 24 12 COPD 12 RTCD</td>
<td>daytime study Increase in pressure or tidal volume Pressure time product measured with esophageal balloon (PTPes)</td>
<td>Pressures above 20-25 cm H2O or volumes above 6 cc/ kg did not produce further drops in PTPes, ventilation did continue to increase although so did leak</td>
<td>Nasal mask Volume ventilator Pressure ventilator</td>
<td>Little gain in increasing PS above 20 in RTCD Respiratory effort minimized below maximum ventilation</td>
</tr>
<tr>
<td>Vianello43 1994 Case controlled Level IV</td>
<td>NMD Duchenne Muscular Dystrophy N = 5 on NPPV but 10 in total</td>
<td>compared 5 with NPPV with another 5 without NPPV but similar characteristics (case control)</td>
<td>NPPV started in the Hospital 3 consecutive nights with overnight NPPV monitoring with transtcutaneous PCO2 monitoring NPPV adjusted so PtcCO2 &lt; 45</td>
<td>Volume Ventilator used Nasal mask</td>
<td>at 24 months 4/5 non NPPV had died 0/5 NPPV group had died at 6 months drop in FVC much lower in NPPV group</td>
</tr>
<tr>
<td>First Author Reference</td>
<td>Disorder/ Patient No.</td>
<td>Design</td>
<td>Titration</td>
<td>Equipment/ Pressure</td>
<td>Outcome/Findings</td>
</tr>
<tr>
<td>------------------------</td>
<td>----------------------</td>
<td>--------</td>
<td>-----------</td>
<td>---------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Ward55 2005</td>
<td>NMD RTCD N = 26 daytime normocapnia and nocturnal hypercapnia most actually MD</td>
<td>Baseline “overnight respiratory sleep study” including SaO₂ and PtPCO₂</td>
<td>NPPV adjusted by overnight “monitoring” separate from initial diagnostic with PSG.</td>
<td>BPAP ST mode pressures not presented nasal or full face masks</td>
<td>Nocturnal PtCO₂ decreased in NPPV group 9/10 in control group deteriorated and treated with NPPV after 8 months</td>
</tr>
<tr>
<td>Randomized controlled trial vs NPPV Manually adjusted overnight with SaO₂, tcPCO₂? EEG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ward55 2005</td>
<td>N = 15 9 COPD 6 Non-COPD OHS, achondroplasia, post-polio, post-TB, ALS, Duchenne MD Chronic hypercapnia 5 patients did not complete study</td>
<td>Received either volume or pressure preset ventilation via mask for 6 weeks, then switched to alternate mode PSG used to assess sleep quality with transcutaneous PCO₂ monitoring Volume NPPV (V-NPPV) and pressure NPPV (P-NPPV) compared</td>
<td>Admitted to hospital for start of NPPV NPPV adjusted to NPPV adjusted to achieve maximal decrease in PCO₂ Supplemental oxygen added to keep SpO₂ &gt; 90% Arterialized ear lobe blood tested</td>
<td>ST/Assist control mode Nasal mask interface Passive humidification Mean values: In pressure mode set peak pressure = 26.6, delivered peak pressure = 22.9 (mbar) Respiratory rate = 20.5 Volume set = 677 ml</td>
<td>Night time PCO₂ decreased in both modes Baseline 54.6 mmHg P-NPPV 46.5 mm Hg V-NPPV 46.2 mmHg Similarly small decrease in daytime PCO₂ in P-NPPV and V-NPPV similar Comparable improvements in sleep quality in both modes More gastric distension in volume mode</td>
</tr>
<tr>
<td>Windisch 55 2005</td>
<td>NMD RTCD N = 26 daytime normocapnia and nocturnal hypercapnia most actually MD</td>
<td>Baseline “overnight respiratory sleep study” including SaO₂ and PtPCO₂</td>
<td>NPPV adjusted by overnight “monitoring” separate from initial diagnostic with PSG.</td>
<td>BPAP ST mode pressures not presented nasal or full face masks</td>
<td>Nocturnal PtCO₂ decreased in NPPV group 9/10 in control group deteriorated and treated with NPPV after 8 months</td>
</tr>
<tr>
<td>Cross-over trial</td>
<td>N = 15 9 COPD 6 Non-COPD OHS, achondroplasia, post-polio, post-TB, ALS, Duchenne MD Chronic hypercapnia 5 patients did not complete study</td>
<td>Received either volume or pressure preset ventilation via mask for 6 weeks, then switched to alternate mode PSG used to assess sleep quality with transcutaneous PCO₂ monitoring Volume NPPV (V-NPPV) and pressure NPPV (P-NPPV) compared</td>
<td>Admitted to hospital for start of NPPV NPPV adjusted to NPPV adjusted to achieve maximal decrease in PCO₂ Supplemental oxygen added to keep SpO₂ &gt; 90% Arterialized ear lobe blood tested</td>
<td>ST/Assist control mode Nasal mask interface Passive humidification Mean values: In pressure mode set peak pressure = 26.6, delivered peak pressure = 22.9 (mbar) Respiratory rate = 20.5 Volume set = 677 ml</td>
<td>Night time PCO₂ decreased in both modes Baseline 54.6 mmHg P-NPPV 46.5 mm Hg V-NPPV 46.2 mmHg Similarly small decrease in daytime PCO₂ in P-NPPV and V-NPPV similar Comparable improvements in sleep quality in both modes More gastric distension in volume mode</td>
</tr>
</tbody>
</table>

RTCD refers to restrictive chest wall disease; NMD, neuromuscular disease; KS, kyphoscoliosis; OHS, obesity hypoventilation syndrome; FFM, full face mask (oronasal); VT-BPAP, volume targeted BPAP; CAH, chronic alveolar hypoventilation; vs, versus; PtPCO₂, transcutaneous PCO₂, IPAP and EPAP in cm H₂O unless specified.